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ABSTRACT
Background: Diabetic nephropathy is the renal complication of diabetes. It is
associated with high mortality, especially for cardiovascular disease. Many of the risk
factors and metabolic features, such as insulin resistant and inflammatory state, are
shared between the renal and cardiovascular complications. Diabetic nephropathy is
known to cluster in families, but its genetic background has not been revealed.
Podocyte injury has a central role in the pathogenesis of diabetic nephropathy, but the
mechanisms are far from completely understood. The studies in this thesis aimed to
increase the knowledge of the pathophysiological processes of diabetic nephropathy
by studying two molecules expressed in podocytes, CD2AP and SHIP2, and by
characterising the development of the renal injury in a mouse model with early-onset
diabetes.
Results: Lipid phosphatase SHIP2 was identified as a new interaction partner of
CD2AP, an adaptor protein essential for podocyte function. SHIP2 was shown to be
expressed in the glomerular podocytes, and to be translocated to the plasma
membrane in response to insulin. The interaction of CD2AP and SHIP2 was not
dependent on insulin stimulation, in contrast, CD2AP was found to bind only to the
non-tyrosine-phosphorylated form of SHIP2. Overexpression of SHIP2 in cultured
podocytes was found to reduce the activation of protein kinase Akt in response to
insulin, and to promote apoptosis. Elevated expression of SHIP2 was detected in the
glomeruli of diabetic mice and rats.
A candidate gene approach was used to investigate if polymorphisms in CD2AP or
INPPL1 (encoding for SHIP2 protein) genes are associated with diabetic nephropathy.
The study subjects were from the Finnish Diabetic Nephropathy Study, and they all
had type 1 diabetes. CD2AP and INPPL1 genes were not associated with diabetic
nephropathy per se, but INPPL1 was associated with the metabolic syndrome in male
patients with diabetes, and CD2AP with end stage renal disease in patients with
diabetes. One of the INPPL1 polymorphisms has previously been reported to be
associated with the components of the metabolic syndrome, and the finding was
repeated in this study, despite totally different study population. The associations
between polymorphisms in the CD2AP gene and end stage renal disease were
confirmed in meta-analysis of the original and additional European cohorts.
The transgenic E1-DN mice express a kinase-negative epidermal growth factor
receptor in their pancreatic islets and are diabetic due to impaired postnatal growth of
?-cell mass. The renal injury is secondary to persistent hyperglycaemia. The
homozygous E1-DN mice were found to develop albuminuria, and histological and
structural changes including mesangial expansion, thickening of the glomerular
basement membrane and podocyte foot process widening. Reduced expression of
nephrin, increased glomerular apoptosis and tubular proliferation were identified as
potential mechanisms of renal injury.
Conclusions: The upregulation of SHIP2 demonstrates a possible mechanism for
insulin resistance in podocytes, and may be involved in increased podocyte apoptosis
in diabetes. The results of the genetic analyses suggest that variants in INPPL1 gene
may contribute to susceptibility to the metabolic syndrome, and variants in the
CD2AP gene to susceptibility to end stage renal disease, in patients with type 1
diabetes. Diabetic E1-DN mice develop substantial albuminuria and glomerular injury
resembling human diabetic nephropathy and can serve as a new model to study the
mechanisms of diabetic nephropathy.
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1  INTRODUCTION
The global prevalence of diabetes is continuously increasing. In 2012 over 371
million people were estimated to have diabetes (International Diabetes Federation
2011), and the number is predicted to rise to 439 million adults with diabetes in 2030
(Shaw, Sicree & Zimmet 2010). The increase is mainly due to the growing prevalence
of type 2 diabetes, especially in developing countries. In addition, a worldwide
increase in the incidence of type 1 diabetes has been reported during the past decades
(Onkamo et al. 1999). In Finland, where the incidence of type 1 diabetes is the highest
in the world, an accelerated increase in incidence in children was observed in the
1990s and in the beginning of this millennium (Tuomilehto et al. 1999, Harjutsalo,
Sjoberg & Tuomilehto 2008), concomitantly with a decrease in the age of onset
(Harjutsalo, Sjoberg & Tuomilehto 2008, Karvonen, Pitkaniemi & Tuomilehto 1999).
Type 1 diabetes is an immune-mediated disease leading to destruction of pancreatic ?-
cells and dependence on exogenous insulin (American Diabetes Association 2013).
Type 1 diabetes has a strong genetic component, mediated mainly through human
leukocyte antigen (HLA) genes, with interactions of predisposing and protective
alleles (Hermann et al. 2003). The destruction of ?-cells is associated with presence of
autoantibodies, and in addition, several environmental factors have been suggested to
trigger the progression to clinical type 1 diabetes (Knip, Simell 2012). Type 2
diabetes is characterised by the combinatory effect of insulin resistance and relative
insulin deficiency, together leading to hyperglycaemia (American Diabetes
Association 2013, Nolan, Damm & Prentki 2011). Genetic susceptibility contributes
to the pathogenesis of type 2 diabetes, and in combination with overnutrition and
inadequate physical activity results in accumulation of visceral fat and an
inflammatory state (Nolan, Damm & Prentki 2011).
The increased morbidity and mortality in diabetes are due to the complications,
defined as microvascular and macrovascular complications. The microvascular
complications include diabetic nephropathy, retinopathy and neuropathy, whereas
macrovascular complications refer to cardiovascular disease, cerebral stroke and
peripheral vascular disease. However, these are not separate entities, but closely
linked together. Diabetic nephropathy is associated with an increased risk for
cardiovascular disease and mortality (Nathan et al. 2005, Groop et al. 2009), and with
the metabolic syndrome, a cluster of cardiovascular risk factors (Thorn et al. 2005).
The underlying pathogenic factor for the metabolic syndrome is insulin resistance,
which is also a risk factor for diabetic nephropathy (Orchard et al. 2002), thus
combining the cardiovascular and renal complications to inflammation and
unfavourable metabolic profile.
In the kidney, the glomerular capillaries are affected by hyperglycaemia, and injury of
glomerular epithelial cells, podocytes, has an important role in the pathogenesis of
diabetic nephropathy. The studies of this thesis were initiated by characterisation of
new interaction partners of the podocyte protein CD2AP, in order to study its role in
podocyte injury. Identification of lipid phosphatase SHIP2, a molecule linked to
insulin resistance and to the metabolic syndrome, among these proteins, led us to
investigate the interaction of CD2AP and SHIP2 in podocytes and their possible role
in diabetic nephropathy.
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2  REVIEW OF THE LITERATURE
2.1  Glomerulus
Nephron, the functional unit of the kidney, consists of a glomerulus and a tubulus,
which can be subdivided into different segments. Primary urine is filtrated from the
plasma through the glomerular filtration barrier to the Bowman’s space of the
glomerulus, from where it passes to the tubular system.
Figure 1. Structure of the glomerulus. Modified from (Kriz, Gretz & Lemley 1998).
2.1.1  Filtration barrier
The glomerular filtration barrier consists of three layers, fenestrated endothelial cells,
glomerular basement membrane (GBM) and podocytes (Figure 2). Podocytes are
specialised epithelial cells with long interdigitating foot processes that surround the
capillaries of the glomerular tuft. Water and small solutes pass the barrier, whereas
the molecules of the size of albumin and larger are retained in the blood (Farquhar,
Wissig & Palade 1961).
The glomerular filtration barrier is also charge selective. Positively charged molecules
penetrate the barrier more easily (Bohrer et al. 1978) due to the negative charge of the
glycocalyx of the endothelial cells and podocytes  ((Hjalmarsson, Johansson &
Haraldsson 2004), as well as of the GBM (Kanwar, Farquhar 1979a). The main
glycoprotein of the podocytes is podocalyxin (Kerjaschki, Sharkey & Farquhar 1984),
and the GBM is composed of large glycoproteins, most abundantly type IV collagen
and laminin (Abrahamson 1987), and heparan sulphate proteoglycans (Kanwar,
Farquhar 1979b).
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There is evidence for the importance of all the three layers in maintaining the
filtration function. First, disruption of the endothelial surface layer by hyaluronidase
(Meuwese et al. 2010) or adriamycin (Jeansson et al. 2009) in mice, has been shown
to lead to proteinuria. Second, defects in the GBM components in laminin ?2-
deficient mice (Noakes et al. 1995, Jarad et al. 2006) or in humans with Alport
syndrome, caused by mutations in type IV collagen (Barker et al. 1990, Kruegel,
Rubel & Gross 2013), result in proteinuria. Podocytes are discussed in more detail.
Figure 2. The three layers of the glomerular filtration barrier. Electron microscopy
image of rat glomerulus.
2.1.2  Podocytes
2.1.2.1 Slit diaphragm
Podocyte foot processes are interconnected with special cell adhesion structures called
slit diaphragms. These zipper-like structures were first visualised by Rodewald and
Karnovski in 1974 with electron microscopy (Rodewald, Karnovsky 1974). The
authors also described a uniform pattern of pores in the structure, with the dimensions
of albumin molecule, suggesting that the slit diaphragm functions as a principal sieve
for plasma proteins. Later, an electron tomography study confirmed and further
defined the structure of the slit diaphragm (Wartiovaara et al. 2004).
2.1.2.2  Podocyte cytoskeleton
Maintaining the cellular architecture is essential for the podocyte function. Podocytes
consist of the cell body, located towards the urinary space, major processes arising
from the cell body and branching into thin foot processes, which surround the
capillaries and attach to the GBM via e.g. integrins (Blattner, Kretzler 2005). Foot
processes have been shown to contain contractile actin filament bundles together with
myosin and alpha-actinin (Drenckhahn, Franke 1988). In contrast, intermediate
filaments and microtubules consisting of vimentin and tubulin were found in the cell
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body and major processes (Drenckhahn, Franke 1988). Regulation of the actin
cytoskeleton is a dynamic process requiring signalling from the slit diaphragm
proteins, from the basal integrin-linked kinase (Blattner, Kretzler 2005) and apical
podocalyxin, which signals through NHERF2 and ezrin proteins (Takeda et al.
2001a).
2.1.2.3  Podocyte proteins
An essential molecule of the slit diaphragm structure is nephrin, the protein encoded
by NPHS1 gene and mutated in the congenital nephrotic syndrome of the Finnish type
(CNF) (Kestila et al. 1998). Nephrin is a transmembrane protein belonging to the
immunoglobulin superfamily of cell adhesion molecules (Kestila et al. 1998), and it is
localised at the slit diaphragm ((Holzman et al. 1999, Ruotsalainen et al. 1999,
Holthofer et al. 1999). Nephrin forms homodimers (Gerke et al. 2003, Khoshnoodi et
al. 2003) that bridge the slit and contribute to the zipper-like structure (Wartiovaara et
al. 2004). In CNF patients and nephrin-deficient mice, the slit diaphragms are absent
(Wartiovaara et al. 2004, Patrakka et al. 2000, Putaala et al. 2001). Nephrin also forms
heterodimers with nephrin-like proteins Neph1, Neph2 and Neph3 (Barletta et al.
2003, Gerke et al. 2005, Heikkila et al. 2011), that are localised at the slit diaphragm
(Barletta et al. 2003, Gerke et al. 2005, Ihalmo et al. 2007). Neph1 is necessary for the
podocyte function, as Neph1 deficient mice develop severe proteinuria and podocyte
foot process disruption (Donoviel et al. 2001). Podocyte slit diaphragms also share
similarities with adherens junctions, and cadherin superfamily proteins, P-Cadherin,
VE-Cadherin and Fat1 have been identified at the slit diaphragm (Reiser et al. 2000,
Cohen et al. 2006, Inoue et al. 2001).
The transmembrane cell adhesion proteins are linked to the actin cytoskeleton and
intracellular signalling networks by several scaffolding proteins. Catenins bind to the
intracellular part of P-Cadherin (Reiser et al. 2000), and zonula occludens-1 to the
Neph family members (Huber et al. 2003a). Podocin, encoded by NPHS2 gene and
mutated in autosomal resessive steroid-resistant nephrotic syndrome (Boute et al.
2000), interacts with the intracellular part of nephrin (Schwarz et al. 2001), and is
essential for the proper function of the nephrin complex (Huber et al. 2003b). Another
adaptor protein crucial for the filtration function is CD2-associated protein (CD2AP),
which is discussed later. Other intracellular nephrin associating cell junction proteins
include IQGAP, MAGI-2, CASK and alpha-actinin (Lehtonen et al. 2005).
In addition to the structural significance, the nephrin complex exhibits signalling
properties. Tyrosine residues of nephrin can be phosphorylated by Src family kinase
Fyn (Verma et al. 2003, Li et al. 2004), triggering binding of the adaptor protein Nck
and inducing actin polymerisation (Verma et al. 2006, Jones et al. 2006). These
mechanisms suggest an important role for nephrin phosphorylation in the regulation
of the actin cytoskeleton (Jones et al. 2009).
Nephrin also interacts with the regulatory subunit of phosphoinositide 3-kinase
(PI3K), and induces activation of the Akt signalling pathway (Huber et al. 2003). This
interaction is increased by nephrin phosphorylation (Zhu et al. 2008). Akt activation
has effects on actin stress fiber formation (Zhu et al. 2008) and acts as a survival
signal in podocytes protecting them from apoptosis (Huber et al. 2003).
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Alpha-actinin-4, a protein cross-linking actin filaments and other molecules, has been
found to be mutated in some forms of focal segmental glomerulosclerosis (FSGS)
(Kaplan et al. 2000). Alpha-actinin functions together with synaptopodin, inducing
elongation of actin filament bundles (Asanuma et al. 2005). Synaptopodin, when
phosphorylated, stabilises the actin cytoskeleton (Faul et al. 2008). Interestingly,
calcineurin dephosphorylates synaptopodin, counteracting this stabilising function.
Calcineurin can be inhibited by drugs, e.g. cyclosporine. Together, this presents a new
mechanism for antiproteinuric effects of calcineurin inhibitors (Faul et al. 2008,
Mathieson 2008).
Mutations in Transient Receptor Potential Cation Channel 6 (TRPC6) have also been
found in FSGS (Winn et al. 2005). This calcium channel is expressed at the slit
diaphragm and interacts with nephrin (Reiser et al. 2005). The effects of calcium
signalling in the podocytes are not fully understood, but calcium is known to
modulate the cytoskeleton via activation of calcineurin and mTOR signalling
(Vassiliadis et al. 2011).
2.1.2.3.1  CD2AP
CD2-associated protein (CD2AP) was first characterised in T-cells where it was
found at the junctions between T-cells and antigen-presenting cells (Dustin et al.
1998). CD2AP is a cytosolic adaptor protein with multiple protein-protein interaction
domains (Dustin et al. 1998, Kirsch et al. 1999). It is widely expressed (Kirsch et al.
1999, Li et al. 2000) with particularly strong expression in the kidney glomeruli (Li et
al. 2000, Lehtonen et al. 2000b). CD2AP interacts with nephrin by its third Src
homology 3 (SH3) domain (Palmen et al. 2002), and binds directly to actin with its
COOH-terminus (Lehtonen, Zhao & Lehtonen 2002). Thus, it functions as a link
between the nephrin complex and the actin cytoskeleton. CD2AP also interacts with
PI3K and participates in the stimulation of Akt signalling together with nephrin and
podocin (Huber et al. 2003).
Figure 3. CD2AP protein structure. CD2AP contains three SH3 domains in the N-
terminal part, a central proline rich region (PR), and a C-terminal coiled coil domain
(CC) (Kirsch et al. 1999).
CD2AP expression is regulated by several transcription factors, including
ubiquitously expressed Sp1 and Sp3 (Xu et al. 2012), cell cycle control factor E2F1
(Zou et al. 2012), and interestingly, cAMP-responsive element-binding protein
(CREB) (Lu et al. 2008). The activity of CREB is controlled by various extracellular
signals activating intracellular protein kinase pathways and calcium signalling
(Shaywitz, Greenberg 1999). However, the differential regulation of CD2AP in
different tissues, or possibly in disease states, has not been investigated.
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Studies on CD2AP-deficient mice indicate that CD2AP is required to maintain the
functional integrity of the glomerular slit diaphragm (Shih et al. 1999). CD2AP -/-
mice develop severe nephrotic syndrome, beginning at the age of two to three weeks
with proteinuria and growth retardation, and leading to death at six to seven weeks of
age (Shih et al. 1999). Histological examination of the mice showed mesangial
deposits and glomerular sclerosis, and electron microscopy revealed podocyte foot
process injury. The lethality and renal failure of the CD2AP -/- mice could be rescued
by podocyte-specific expression of CD2AP, indicating that the phenotype is due to
the lack of CD2AP in podocytes and not mediated e.g. by immune cells
(Grunkemeyer et al. 2005).
Heterozygous mice lacking one allele of CD2AP have been shown to develop
glomerular abnormalities, including mesangial expansion, at nine months of age (Kim
et al. 2003). The heterozygous mice did not have proteinuria unless exposed to
additional stress, but they were more susceptible to glomerular damage than wild-type
mice, when injected with a nephrotoxic antibody (Kim et al. 2003). Further, mouse
models of combined heterozygosity of CD2AP and synaptopodin or Fyn proto-
oncogene have been shown to develop FSGS resembling phenotypes (Huber et al.
2006).
Mutations in CD2AP have also been reported in human patients with FSGS (Kim et
al. 2003, Gigante et al. 2009). Besides heterozygous mutations, FSGS patients with
homozygous CD2AP mutation or with bigenic heterozygous mutations of NPHS2 and
CD2AP have been reported (Lowik et al. 2007, Lowik et al. 2008).
2.1.3  Glomerular blood flow
The afferent arterioles conduct blood from the renal interlobular arteries to the
capillaries of the glomerular tuft. Glomerular capillaries converge to a second,
efferent, arteriole, and thus form a unique high-pressure capillary system. The
complex regulation of renal blood flow includes paracrine factors, e.g. kinins, nitric
oxide (NO) and endothelin-1 (ET-1), endocrine regulation, e.g. antidiuretic hormone
and atrial natriuretic peptide, sympathetic nervous system, and renin-angiotensin-
aldosterone system with both paracrine and systemic effects.
2.1.3.1  Juxtaglomerular apparatus
Special epithelial cells of the distal tubulus form a region called macula densa at the
site where the tubulus contacts the glomerulus and the afferent arteriole of the same
nephron. These cells sense the increased delivery of sodium and chloride as a
consequence of increased glomerular filtration and fluid flow, and consequently
release paracrine factors to induce contraction of the afferent arteriole. In addition,
macula densa cells together with baroreceptor cells in the afferent arteriole regulate
the release of renin from the adjacent juxtaglomerular cells, reviewed in (Kurtz 2011).
In the circulation, renin converts angiotensinogen to angiotensin I, which is
subsequently converted to angiotensin II (Ang II) by angiotensin-converting enzyme
(ACE). Ang II is a potent vasoconstrictor, affecting systemic blood pressure as well as
the intraglomerular pressure. Ang II also stimulates aldosterone secretion from the
adrenal gland, resulting in salt retention and further elevation of blood pressure,
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reviewed in (Ruggenenti, Cravedi & Remuzzi 2010). Renin-angiotensin-aldosterone
system is activated in diabetes and has an important role in the pathogenesis of
diabetic nephropathy as discussed later.
2.2 Diabetic nephropathy
2.2.1  Definition of diabetic nephropathy
Diabetic nephropathy is a diabetes-induced kidney disease, characterised by
progressive albuminuria and decline in the glomerular filtration rate (GFR), leading
eventually to end-stage renal disease (ESRD). The first sign of diabetic nephropathy
is persistent microalbuminuria, defined as albumin excretion rate (AER) 20-200
?g/min or 30-300 mg/24 h, and often referred as incipient nephropathy.
Macroalbuminuria, defined as AER >200 ?g/min or >300 mg/24 h, or proteinuria
>500mg/24 h are considered as overt nephropathy. Decreased estimated glomerular
filtration rate (eGFR) <60 ml/min/1.73 m2 can also be considered as a manifestation
of overt diabetic nephropathy (Reutens, Atkins 2011).
2.2.2  Epidemiology of diabetic nephropathy
Diabetic nephropathy is the major cause of ESRD in Europe (Kramer et al. 2009), the
United States (U.S. Renal Data System 2012) and Australia (Australia and New
Zealand Dialysis and Transplant Registry), and it accounts for a significant proportion
of the increase in the need of renal replacement therapy. This is mainly due to the
global increase in the incidence of type 2 diabetes, accompanied by the fact that
improved management allows patients to live longer and consequently to develop
ESRD (Ritz et al. 1999).
A decrease in the incidence of diabetic nephropathy in patients with type 1 diabetes
has been observed in many studies. In cohorts diagnosed before 1960, the cumulative
incidence of diabetic nephropathy was reported to be 35% (Krolewski et al. 1985) or
45% (Andersen et al. 1983) after 40 years of diabetes. Within these cohorts, the
patients with earlier diagnosis had the highest risk for nephropathy. Later studies have
shown that the decreasing trend continues. In Denmark, the 20-year cumulative
incidence of diabetic nephropathy was 31% for patients diagnosed in years 1965-
1969, but only 14% for patients diagnosed in 1979-1984 (Hovind et al. 2003). The
Diabetes Control and Complications Trial (DCCT) study showed that intensive
therapy, which has thereafter become the standard, could reduce the 30-year
cumulative incidence of nephropathy to 9%, compared to 25% in the control group
(Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) Research Group et al. 2009). However, in the
Pittsburgh Epidemiology of Childhood-Onset Diabetes Complications Study, there
was no significant decline in the incidence of nephropathy when patients were divided
in groups according to the year of diagnosis, and the 25-year cumulative incidence
was 32% (Pambianco et al. 2006). Despite the lack of decline in the incidence of
proteinuric nephropathy, the same study showed a significant decrease from 31% to
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18% in the 30-year cumulative incidence of ESRD in patients diagnosed in 1965-1969
compared to those diagnosed in the 1950s. Similar trend was observed in Finland,
where the overall 30-year cumulative incidence of ESRD was 7.8% (Finne et al.
2005).
For type 2 diabetes, there is less follow-up data available. The cumulative incidence
of microalbuminuria after 5 years of the diagnosis of type 2 diabetes has been
reported to be 23% (Gall et al. 1997), and the 8-year cumulative incidence of overt
nephropathy 3.8% (Adler et al. 2003). In an Italian study, the risk of chronic renal
failure, defined by plasma creatinine values >2.0 mg/dl or ESRD, and adjusted for
competing mortality, was 9.3% after 30 years of diabetes diagnosis (Bruno et al.
2003).
2.2.3  Clinical course of diabetic nephropathy
2.2.3.1  Albumin excretion rate
The classical course of diabetic nephropathy progresses through microalbuminuria to
macroalbuminuria and subsequently to ESRD. Increased AER as a predictor of
diabetic nephropathy was described in the early 1980s (Viberti et al. 1982, Mogensen,
Christensen 1984, Parving et al. 1982). In these studies the clear majority (60-85%) of
patients with microalbuminuria progressed to macroalbuminuria. A considerably
lower risk (18.2-30%, follow-up period 7.3-10 years) of progression has been
observed in later studies (Forsblom et al. 1992, Caramori, Fioretto & Mauer 2000),
presumably because of better treatment of both hyperglycaemia and hypertension.
Regression of persistant microalbuminuria has also been reported (Perkins et al. 2003,
Hovind, Tarnow & Parving 2004). In the first study describing the predictive value of
microalbuminuria in type 2 diabetes, the progression rate to proteinuria was 22%
during ten years follow-up (Mogensen, Christensen 1984), but the mortality rate was
remarkably high (77.6%) in that study. Other studies of type 2 diabetes have
suggested a risk of 35-40% for progression from microalbuminuria to proteinuria in 5-
6 years follow-up (Caramori, Fioretto & Mauer 2000).
2.2.3.2  Glomerular filtration rate
2.2.3.2.1  Hyperfiltration
Increased GFR has been reported to be common in early diabetes and to precede the
increase in albuminuria (Wiseman et al. 1985, Caramori et al. 1999). Hyperfiltration
is related to hyperglycaemia (Wiseman et al. 1985), and has been associated with an
increased risk of progression to diabetic nephropathy in a meta-analysis (Magee et al.
2009). However, in two recent studies (Ficociello et al. 2009, Thomas et al. 2012),
baseline hyperfiltration did not predict the development of microalbuminuria. Thus,
its role in progression remains uncertain, and may have changed along better
glycaemic control.
2.2.3.2.2  Decline in GFR
During the course of diabetic nephropathy, the gradual decrease in GFR leads to
impaired renal function. The linear decrease in GFR in patients with type 1 diabetes
and proteinuria was characterised over 30 years ago (Mogensen 1976, Viberti et al.
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1983), and then reported to range from 4.5 to 20 ml/min/1.73m2 per year. A recent
study confirmed a linear or near-linear pattern of the decline in GFR in most of the
patients with type 1 diabetes and proteinuria (Skupien et al. 2012). The median yearly
decline in GFR was 2.9 ml/min/1.73m2, and there was large inter-individual variation
in the slopes, as reported also in the earlier studies. The early decline in GFR
predicted well the later risk of ESRD.
Renal insufficiency can develop also without preceding albuminuria, as observed in
the DCCT/EDIC study (Molitch et al. 2010), where 24% of the patients that
developed impaired eGFR (<60ml/min/1.73m2) had normal AER. However,
macroalbuminuria was associated with highly increased risk of eGFR loss. Also other
studies have reported impaired renal function (Caramori, Fioretto & Mauer 2003,
Perkins et al. 2010) and diabetic glomerular lesions (Caramori, Fioretto & Mauer
2003) in patients with type 1 diabetes and normal AER. For patients with type 2
diabetes, progression to renal insufficiency without albuminuria is even more
common (MacIsaac et al. 2004, Kramer et al. 2003).
2.2.4  Clinical risk factors of diabetic nephropathy
The prevention of diabetic nephropathy is based on treating the modifiable risk
factors: hyperglycaemia, hypertension and dyslipidemia. The improvements in these
factors can be achieved by life style changes, e.g. dietary interventions, physical
activity and quiting smoking, or by medications. However, more longitudinal data are
needed to clarify the effects of various interventions on the risk of nephropathy.
2.2.4.1  Increase in albumin excretion rate
Increased AER, even below the limit of microalbuminuria, can be seen either as a risk
factor for nephropathy because of its predictive value (Hovind et al. 2004, Vergouwe
et al. 2010), or as a marker of the initiation of the disease process, as discussed above.
2.2.4.2  Poor glycaemic control
Hyperglycaemia is the main causative factor for diabetic complications, and therefore
poor glycaemic control imposes an increased risk for nephropathy on patients with
diabetes, as demonstrated by several studies (EURODIAB 1994, UK Prospective
Diabetes Study (UKPDS) Group 1998, Olsen et al. 2000, Rossing, Hougaard &
Parving 2005, Hovind et al. 2001). In the DCCT study, intensified therapy, meaning
insulin pump or multiple daily insulin injections compared to one or two injections in
the standard therapy group, reduced glycated hemoglobin (HbA1c) levels significantly
(7.4% vs. 9.1%), and this was associated with 39% reduction in the risk of
microalbuminuria (Diabetes Control and Complications Trial Research Group 1993).
In the follow-up, 12 years after the closeout of the trial, the HbA1c levels were  similar
between the groups, but the effect of the period of better glycaemic control persisted
and the risk of overt nephropathy was significantly reduced (Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) Research Group et al. 2009). Parallel with the DCCT Study, a Swedish
study showed a reduction in the incidence of nephropathy obtained by intensified
treatment (Reichard, Nilsson & Rosenqvist 1993). The question of risk in relation to
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the degree of hyperglycaemia was addressed in two studies, showing that the
prevalence of microalbuminuria rose steeply with HbA1 values above 10.1%
(corresponding HbA1c 8.1%) (Krolewski et al. 1995), and that the risk of progression
from microalbuminuria to nephropathy in 4 years follow-up was significantly lower
for patients with HbA1c below 8.0% (Warram et al. 2000). Similarly, in type 2
diabetes, reduction of HbA1c has been reported to reduce the overall risk for
microvascular complications (Stratton et al. 2000, Zoungas et al. 2012). Regarding the
development of nephropathy, lower HbA1c level reduced the risk for
microalbuminuria and macroalbuminuria, but not ESRD in a relatively short follow-
up of 5 years (Ismail-Beigi et al. 2010). However, intensive glucose lowering therapy
aiming to HbA1c level below 6%, was observed to increase all-cause mortality as well
as the risk of hypoglycaemia and weight gain in patients with type 2 diabetes (Action
to Control Cardiovascular Risk in Diabetes Study Group et al. 2008).
2.2.4.3  Hypertension
Elevated blood pressure is an important factor in the course of diabetic nephropathy,
and an essential component of the disease. Blood pressure has been reported to rise
after the initiation of microalbuminuria (Mathiesen et al. 1990) and in parallel with
the development of proteinuria (Hasslacher et al. 1985). Concomitantly, hypertension
increases the risk of progression to overt nephropathy (Adler et al. 2000) and the
decline in GFR (Hovind et al. 2001, Rossing et al. 2004), in both type 1 and type 2
diabetes. Impaired renal function then induces further elevation of blood pressure.
2.2.4.4  Dyslipidemia
Lipid abnormalities are an early finding in patients with type 1 diabetes and
albuminuria (Groop et al. 1996, Jenkins et al. 2003), and have been shown to predict
progression of nephropathy (Mulec et al. 1993, Thomas et al. 2006, Tolonen et al.
2009). Different lipid particles may affect the progression on different stages of the
disease; total cholesterol, low density lipoprotein, and triglycerides have all been
implicated (Thomas et al. 2006, Tolonen et al. 2009).
2.2.4.5  Smoking
Cigarette-smoking has been associated with an increased risk for both
microalbuminuria (Forsblom et al. 1998) and overt nephropathy (Muhlhauser,
Sawicki & Berger 1986, Rossing, Hougaard & Parving 2002). In a small prospective
study, an association between smoking and progression of nephropathy was also
observed (Sawicki et al. 1994). However, in a Danish study, smoking was not
associated with a decline in GFR in patients with type 1 diabetes (Hovind et al. 2003,
Hovind et al. 2003). In that study smoking was defined as smoking one or more
cigarettes per day. In patients with type 2 diabetes, heavy smoking (defined as
smoking 20 cigarettes or more per day more that 50% of the follow-up period), was
associated with the rate of GFR decline (Rossing et al. 2004). Thus, the number of
cigarettes might influence the effect of smoking, and explain the differences in
associations reported in different studies.
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2.2.5 Association of diabetic nephropathy with other complications
2.2.5.1  Diabetic retinopathy
Diabetic retinopathy is a vision-threatening microvascular complication of diabetes.
Diabetic nephropathy in patients with type 1 diabetes is regularly accompanied with
diabetic retinopathy (Nilsson et al. 1967, Hietala et al. 2008). In addition, diabetic
glomerular lesions have been associated with the severity of diabetic retinopathy
(Klein et al. 2005), and baseline proteinuria with the risk of proliferative retinopathy
in 25-years follow-up (Klein et al. 2008).
2.2.5.2  Cardiovascular disease and mortality
Diabetic nephropathy is strongly associated with cardiovascular disease (Nathan et al.
2005). Already in the 1980s, microalbuminuria and proteinuria were shown to predict
all-cause mortality in diabetes (Borch-Johnsen, Andersen & Deckert 1985, Mogensen
1984). Although uraemia was then an important cause of death for patients with
nephropathy, also the association between proteinuria and cardiovascular deaths was
observed (Borch-Johnsen, Andersen & Deckert 1985). Subsequently, both
microalbuminuria and proteinuria have been shown to predict cardiovascular
mortality in patients with type 1 diabetes (Borch-Johnsen, Kreiner 1987, Messent et
al. 1992), and correspondingly, macroalbuminuria has been identified as a major risk
factor for cardiovascular mortality in type 2 diabetes (Gall et al. 1995, Bruno et al.
2005). In a recent publication from the Finnish Diabetic Nephropathy Study
(FinnDiane), microalbuminuria increased the risk of death only slightly, whereas
more advanced nephropathy influenced it significantly (Groop et al. 2009). A large
proportion of patients with macroalbuminuria die before developing ESRD, and for
patients with type 2 diabetes and overt nephropathy, the risk of death exceeds the risk
of renal failure (Adler et al. 2003). In contrast, for patients with type 1 diabetes and
macroalbuminuria, ESRD appears as the more probable outcome (Forsblom et al.
2011).
2.2.6  Pathology of diabetic nephropathy
2.2.6.1  Histology
The characteristic pathologic feature of diabetic nephropathy is mesangial matrix
accumulation, first reported by Kimmelstiel and Wilson in 1936 (Kimmelstiel, Wilson
1936). They described intercapillary hyalinous lesions, typically in a nodular shape,
which are now often called Kimmelstiel-Wilson nodules, and represent the severe
stage of nephropathy (Tervaert et al. 2010). The mesangial expansion commences in a
milder and more diffuse pattern, and subsequently leads to glomerular sclerosis as the
disease progresses (Fioretto, Mauer 2007). The degree of mesangial expansion has
been correlated with clinical findings of nephropathy and progression in albumin
excretion (Mauer et al. 1984, Fioretto et al. 1995). In addition to glomerular lesions,
arterial hyalinosis, tubular atrophy and interstitial fibrosis are observed in advanced
nephropathy (Fioretto, Mauer 2007, Bader et al. 1980). In type 2 diabetes, the
histological findings are more diverse, and instead of classical glomerular lesions, part
of the patients have predominantly tubulointerstitial disease (Dalla Vestra et al. 2000)
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2.2.6.2  Structural changes
On electron microscopic level, the main finding of diabetic nephropathy is thickening
of the glomerular basement membrane (GBM) (Fioretto et al. 1995, Osterby 1972).
GBM thickening is observed early in type 1 diabetes (Osterby 1972), but has been
reported to remain stable in the follow-up (Fioretto et al. 1995) and not to correlate
with the severity of the clinical disease (Mauer et al. 1984). Renal biopsies of patients
with diabetes and increased AER have revealed also widening of podocyte foot
processes (Ellis et al. 1987, Berg et al. 1998), and even detachment of podocytes from
GBM (Toyoda et al. 2007). Both of these processes have been described in other
proteinuric diseases (Farquhar, Vernier & Good 1957, Grishman, Churg 1975), and
considered essential in the pathogenesis of proteinuria and glomerular sclerosis.
2.2.7  Genetics of diabetic nephropathy
Familial clustering of diabetic nephropathy has been reported in several studies
(Seaquist et al. 1989, Diabetes Control and Complications Trial Research Group.
1997, Harjutsalo et al. 2004), suggesting genetic contribution to the disease
susceptibility, but the extensive search for diabetic nephropathy genes has not
revealed strong associations.
Several studies have initially reported associations of candidate genes with diabetic
nephropathy. However, the results from replication studies have not been consistent.
A recently published meta-analysis combined previously published data from both
type 1 and type 2 diabetes and different ethnicities, and found 24 polymorphisms to
be associated with diabetic nephropathy (Mooyaart et al. 2011). The most studied
genetic variant was a polymorphism in angiotensin 1-converting enzyme (ACE) gene
(Hadjadj et al. 2007), which proved significant in the meta-analysis. The other
interesting candidates included ELMO1 gene, which had previously been implicated
in several populations, erythropoietin, vascular endothelial growth factor A (VEGF-
A), apolipoproteins APOE and APOC1, and FRMD3 and CARS genes, which both
had two associated variants. All these polymorphisms together with the eight most
significant SNPs from the Genetics of Kidneys in Diabetes US (US-GOKinD) study
(Pezzolesi et al. 2009), were examined in the Genetics of Nephropathy –an
International Effort (GENIE) consortium study (Williams et al. 2012), combining data
of the US-GOKinD, Warren 3/Genetics of Kidneys in Diabetes UK and All-Ireland
(UK-ROI) collection and the FinnDiane study. In this meta-analysis of three large
type 1 diabetes cohorts, only one polymorphism in erythropoietin gene promoter
retained genome-wide significance for the association with the combined phenotype
of ESRD and proliferative retinopathy. In addition, two SNPs downstream of FRMD3
were found to be associated with diabetic nephropathy with experiment wide
significance, but all other variants were negative.
In a later publication from the GENIE consortium, the three genome-wide association
studies (GWAS) were combined in a meta-analysis, which identified an intronic SNP
in the ERBB4 gene to be associated with diabetic nephropathy (Sandholm et al.
2012). The association was not statistically significant on the genome-wide level, but
the effect was consistent in all the three populations. ERBB4 encodes a tyrosine
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kinase receptor, belonging to epidermal growth factor receptor family, and is involved
in tubular development (Veikkolainen et al. 2012).
Besides the ERBB4 SNP for diabetic nephropathy, the GENIE study found a SNP in
AFF3 gene, encoding a transcription factor, to be associated with ESRD when
compared to all other patients (Sandholm et al. 2012). This hit was further confirmed
by an additional meta-analysis including the original and nine additional cohorts. The
meta-analysis identified also another marker with genome-wide significance for
ESRD at an intergenic location in chromosome 15.
2.2.8 Mechanisms of diabetic nephropathy
2.2.8.1  Hyperglycaemia
The excess of intracellular glucose is the initial factor for hyperglycaemia-induced
cellular injury. Thus, the cell types that take up glucose continuously are more
vulnerable to damage. The biochemical mechanisms of cellular injury induced by
excess of glucose have been presented and reviewed in detail by Michael Brownlee
(Brownlee 2001, Brownlee 2005).
Cytosolic glucose is normally metabolised through the glycolysis pathway into
pyruvate, which is subsequently converted into acetyl coenzyme A (acetyl CoA) by
oxidative decarboxylation inside mitochondria. Acetyl CoA is completely oxidised by
the citric acid cycle and electrons are transferred to oxygen through the electron
transport chain in the inner mitochondrial membrane. Excess of glucose can activate
alternative metabolic pathways at several steps of glucose metabolism, e.g. the polyol
and the hexosamine pathways, with potential harmful effects (Lee, Chung 1999,
Marshall, Bacote & Traxinger 1991).
Importantly, the excess of glucose also leads to formation of reactive oxygen species
(ROS) when the mitochondrial electron transport chain becomes oversaturated. After
a critical threshold in the voltage across the membrane, the electrons are donated to
molecular oxygen, and superoxide is created (Korshunov, Skulachev & Starkov
1997). This hyperglycaemia-induced ROS production has been shown to be prevented
if pyruvate transport to mitochondria is blocked or if the electron transport chain is
inhibited (Nishikawa et al. 2000). Further, degradation of superoxide by
overexpression of superoxide dismutase inhibits the formation of ROS (Nishikawa et
al. 2000), implicating this pathway as the primary source of increased ROS in
hyperglycaemia.
2.2.8.1.1  Protein kinase C
Intracellular excess of glucose causes activation of protein kinase C (PKC) via
increase in the second messenger diacylglycerol (DAG), which is synthesised from
glycolytic metabolites (Xia et al. 1994a). The increase of DAG and subsequent
activation of PKC has been observed both in animal models of diabetes and in vitro
assays exposing cells to high glucose (Xia et al. 1994a). The activation of PKC has
several deleterious downstream effects. It has been shown to decrease the expression
of endothelial nitric oxide synthase (eNOS) (Kuboki et al. 2000), and to increase the
expression of vascular endothelial growth factor (VEGF) (Williams et al. 1997) and
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of transforming growth factor ? (TGF-?) (Koya et al. 1997). Treatment of diabetic
rodents with PKC-? inhibitor attenuated the diabetes-induced increase in GFR and
AER (Ishii et al. 1996), as well as mesangial expansion (Koya et al. 2000), further
suggesting a role for PKC in diabetic complications.
2.2.8.1.2  Advanced glycation end-products
Intracellular production of advanced glycation end-products (AGEs) is mediated
mainly by dicarbonyls like methylglyoxal (Shinohara et al. 1998), a reactive substrate
formed form glyceraldehyde-3-phosphate (Thornalley 1990) in excess of glucose. The
AGE precursors react with carbonyl groups of intracellular proteins causing
modification in their function (Yao et al. 2007), as well as extracellular matrix
proteins and plasma proteins, leading to circulating AGE proteins.
2.2.8.2  Activation of receptor for AGEs in the kidney
The receptor for AGEs (RAGE) is a multiligand immunoglobulin superfamily
receptor, first identified as a receptor for AGEs (Neeper et al. 1992). Later, RAGE has
been found to bind also other ligands, like S100/calgranulin polypeptides that are
secreted in inflammation (Zimmer et al. 1995, Hofmann et al. 1999), and to activate
NF-?B through MEK and MAP kinases (Lander et al. 1997). NF-?B is a transcription
factor involved in inflammatory response (Tornatore et al. 2012), and shown also to
activate nephrin and Neph3 transcription (Ristola et al. 2012). In addition, NF-?B has
been reported to be activated in the kidneys of human patients with type 2 diabetes
(Mezzano et al. 2004). Constitutive activation of NF-?B in a transgenic mouse model
induced proteinuria, glomerular sclerosis and podocyte foot process injury (Hussain et
al. 2009).
RAGE can be shed from the cellular membrane to form soluble RAGE, which binds
ligands and antagonises RAGE signalling (Zhang et al. 2008). RAGE-mediated
signalling seems to contribute to the pathogenesis of diabetic nephropathy, as
treatment with RAGE neutralising antibody significantly attenuated the renal injury in
both db/db mice and mice with streptozotocin induced diabetes, models for type 2 and
type 1 diabetes, respectively (Flyvbjerg et al. 2004, Jensen et al. 2006). Similar results
were obtained by treating db/db mice with soluble RAGE (Wendt et al. 2003).
Furthermore, RAGE deficiency or treatment with AGE inhibitor partially protected
diabetic mice from the renal injury (Tan et al. 2010).
2.2.8.3  Renin-angiotensin-aldosterone system
Renin-angiotensin-aldosterone system (RAAS) controls systemic blood pressure and
fluid and electrolyte balance, and has also important intrarenal functions. The
intrarenal effects were first demonstrated in dogs by an intrarenal infusion of an Ang
II antagonist, which increased renal blood flow and GFR (Kimbrough et al. 1977).
The components of RAAS are expressed widely in the different cell types of the
kidney, and in addition to the control of blood flow, Ang II acts as an autocrine and
paracrine signal within the glomerulus. It has been shown to act as a profibrotic signal
by upregulating TGF-? in mesangial cells and subsequently inducing extracellular
matrix production (Kagami et al. 1994). In experimental diabetes, both the production
of Ang II and the expression of its receptor AT1R are increased in podocytes (Yoo et
al. 2007), and in vitro studies have shown that exposure to high glucose increases
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production of Ang II in cultured podocytes and mesangial cells (Durvasula et al.
2004, Vidotti et al. 2004). In addition, mechanical strain on cultured podocytes
activated the local angiotensin system possibly reflecting the stress caused in vivo by
increased intraglomerular pressure (Durvasula, Shankland 2008). Ang II signalling
has been shown to induce remodelling of podocyte cytoskeleton and consequently
alter nephrin expression (Hsu et al. 2008, Doublier et al. 2003a), which might
contribute to the development of proteinuria.
There is wide evidence from clinical studies that RAAS inhibition has beneficial renal
effects beyond the blood pressure lowering effect. Mathiesen et al. reported in 1991
that an ACE inhibitor (captopril) postponed development of overt nephropathy in
normotensive diabetic patients with microalbuminuria (Mathiesen et al. 1991), and
Björck et al showed that enalapril delayd the progression of established diabetic
nephropathy by reducing AER and the rate of GFR decline (Bjorck et al. 1992). After
these studies, larger randomized trials have confirmed the renoprotective effects of
ACE inhibitors (Lewis et al. 1993, Heart Outcomes Prevention Evaluation (HOPE)
Study 2000) and Ang II receptor blockers (Parving et al. 2001) in patients with
incipient or overt nephropathy and either type 1 or type 2 diabetes. However, results
from RAAS inhibition in preventing microalbuminuria have not been as promising or
consistent (EUCLID Study Group 1997, Ruggenenti et al. 2006).
2.2.8.4  Growth factors
2.2.8.4.1  TGF-?
Transforming growth factors are polypeptides that induce collagen formation and are
involved in wound healing (Sporn et al. 1983). TGF-? is an important regulator of
glomerular extracellular matrix production by both mesangial cells (Okuda et al.
1990) and podocytes (Nakamura et al. 1992), and has been implicated in the
mesangial expansion in diabetes. Increased expression of TGF-? has been detected in
diabetic rat and human glomeruli (Yamamoto et al. 1993, Wahab et al. 2005, Lane,
Snelling & Langer 2001), together with accumulation of fibronectin (Yamamoto et al.
1993). Further, treatment of diabetic db/db mice with neutralizing TGF-? antibodies
prevented glomerular sclerosis and plasma creatinine elevation, but not proteinuria
(Ziyadeh et al. 2000). Glomerular expression of TGF-? in diabetes has been shown to
be induced by both Ang II (Kagami et al. 1994) and RAGE (Wendt et al. 2003). In
addition to the profibrotic effects, TGF-? promotes podocyte apoptosis (Schiffer et al.
2001).
2.2.8.4.2  CTGF
Connective tissue growth factor (CTGF) is expressed by both mesangial cells and
podocytes, and has been reported to be upregulated in glomeruli of patients with
diabetic nephropathy (Wahab et al. 2005, Umezono et al. 2006). The increased
expression of CTGF was observed already at the early stages of nephropathy with
microalbuminuria (Wahab et al. 2005) or mild glomerular lesions (Umezono et al.
2006). CTGF activation is a downstream effect of TGF-? (Colwell et al. 2005), and
has been shown to mediate increased fibronectin production induced by high glucose
(Wahab et al. 2005).
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2.2.8.4.3  VEGF-A
Vascular endothelial growth factor A (VEGF-A) is a secreted angiogenic growth
factor (Leung et al. 1989) expressed in podocytes (Simon et al. 1995) and involved in
nephrogenesis (Tufro et al. 1999). The autocrine VEGF-A signalling acts as a survival
signal in podocytes, and reduces apoptosis (Foster et al. 2005, Guan et al. 2006).
VEGF-A also promotes phosphorylation of nephrin (Foster et al. 2005) and
upregulates expression of podocin (Guan et al. 2006) in cultured podocytes. However,
overexpression of VEGF-A in a transgenic mouse model caused podocyte injury and
albuminuria (Veron et al. 2010). In diabetes, an increase in the VEGF-A level has
been observed both in the circulation in patients with diabetic nephropathy (Hovind et
al. 2000) and in renal biopsies of early nephropathy (Shulman et al. 1996). In
addition, blocking VEGF-A with inhibitory antibodies attenuated the renal changes in
diabetic rat and mice (de Vriese et al. 2001, Flyvbjerg et al. 2002). Based on these
results, upregulation of VEGF-A has been suggested to be a harmful mechanism in
the development of diabetic nephropathy. However, a recently published study
showed that VEGF-A signalling is needed in diabetes. Mice with podocyte-specific
inducible deletion of VEGF-A and diabetes developed more severe glomerular injury
when compared to wild-type mice with diabetes (Sivaskandarajah et al. 2012). Thus,
the upregulation of VEGF-A in diabetic glomeruli might represent a compensatory or
protective response to hyperglycaemia, but more studies are needed to define its role.
2.2.8.5  Podocyte apoptosis
Reduced number of podocytes has been observed in renal biopsies from patients with
either type 1 or type 2 diabetes (Steffes et al. 2001, Pagtalunan et al. 1997a), and
podocyte loss has also been shown to predict the progression of albuminuria in type 2
diabetes (Meyer, Bennett & Nelson 1999). Podocyte depletion can result from
apoptosis, which has been described in kidney samples of human patients with
diabetes (Verzola et al. 2007b) and streptozotocin-treated diabetic rats (Menini et al.
2007).
Reactive oxygen species (ROS), stimulated by high glucose, were shown to induce
podocyte apoptosis via activation of p38 mitogen activated protein (MAP) kinase and
caspase-3 in cultured podocytes and in mouse models of diabetes (Susztak et al.
2006). In addition, MAP kinase mediated podocyte apoptosis is induced by TGF-?
(Schiffer et al. 2001). High glucose, ROS and TGF-? also induce apoptosis in a
calcium and calcineurin dependent manner (Gooch et al. 2004), mediated by
activation of the calcium channel TRPC6 (Liu et al. 2013) and leading to activation of
nuclear factor of activated T cells (NFAT) transcription factors (Li et al. 2013, Wang
et al. 2011) and subsequent increase in proapoptotic protein Bax (Li et al. 2013)(Li).
Furthermore, Ang II has been shown to promote podocyte apoptosis (Ding et al.
2002), at least in part through activation of the calcineurin/NFAT pathway and a
positive feedback loop upregulating TRPC6 (Nijenhuis et al. 2011). Several other
molecules, e.g. the Notch pathway (Niranjan et al. 2008) and tumor suppressor p53
(Eid et al. 2010), have been implicated in the complex intracellular signalling network
regulating podocyte apoptosis.
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway and extracellular signal-
regulated kinase (ERK) 1/2 pathway have been identified as anti-apoptotic pathways
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in podocytes, and their activation has been found to involve nephrin and CD2AP
(Huber et al. 2003, Schiffer et al. 2004).
2.2.8.6 Inflammation
Diabetic nephropathy is associated with chronic low-grade inflammation.
Hyperglycaemia-induced oxidative stress promotes acute inflammation, which is
sustained by NF-?B activation mediated by PKC (Yerneni et al. 1999) and RAGE
signalling (Lander et al. 1997). Sustained activation of NF-?B is observed in
diabetes(Bierhaus et al. 2001). This potentiates the inflammatory response by
activating proinflammatory genes, including upregulation of RAGE. Also RAGE
ligands, including AGEs, S100 inflammatory proteins and high-mobility group box-1
(HMGB1), are elevated in diabetes (Kosaki et al. 2004, Yan et al. 2009). In addition,
RAGE activation induces expression of monocyte chemoattractant protein-1 (MCP-1)
(Marsche et al. 2007) and promotes leukocyte recruitment through interaction with
integrins (Chavakis et al. 2003). MCP-1 mediated macrophage accumulation has been
shown to contribute to renal injury in mouse models of type 1 and type 2 diabetes
(Chow et al. 2006, Chow et al. 2007).
C-reactive protein (CRP) is an acute-phase protein produced by the liver, and a
marker of systemic inflammation. CRP has been reported to be slightly elevated in
patients with type 1 diabetes, even without clinical complications (Schalkwijk et al.
1999). Further increase in CRP has been associated with increased AER (Schalkwijk
et al. 1999, Saraheimo et al. 2003) in type 1 diabetes, and with progression of
albuminuria in patients with type 2 diabetes (Stehouwer et al. 2002). CRP levels have
been shown to correlate with interleukin (IL)-6 (Bataille, Klein 1992). Accordingly,
an elevation of IL-6 level has been reported in patients with both type 1 and type 2
diabetes (Myrup et al. 1996, Pickup et al. 2000), and it has been associated with
albuminuria (Saraheimo et al. 2003). The other inflammatory cytokines implicated in
diabetic nephropathy include IL-1 (Sassy-Prigent et al. 2000) and tumour necrosis
factor-? (TNF-?) (Navarro et al. 2005), which have been shown, together with IL-6,
to be upregulated in glomeruli in experimental diabetes (Navarro et al. 2006).
Importantly, this upregulation was associated with AER, and reduced by ACE
inhibitor treatment, connecting inflammation also to RAAS (Navarro et al. 2006).
Inflammation is involved in endothelial dysfunction, which is an important factor in
the pathogenesis of microvascular complications of diabetes (Goldberg 2009).
Inflammatory markers have been associated with markers of endothelial dysfunction,
e.g. von Willebrand factor and tissue plasminogen activator, as well as with clinical
risk factors for vascular disease, in patients with type 1 diabetes (Romano et al. 2001,
Schram et al. 2003). Endothelial dysfunction includes also reduced production of
vasodilator NO (Hoshiyama et al. 2003), increased production of vasoconstrictor
Endothelin-1 (Spirig et al. 2009), and increased expression of the proinflammatory
adhesion molecules ICAM-1 and VCAM-1 in glomerular endothelial cells (Sassy-
Prigent et al. 2000).
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Figure 4. An overview of the pathogenic mechanisms involved in the development of
diabetic nephropathy. ROS: reactive oxygen species; PKC: protein kinase C; AGE:
advanced glycation end products; RAGE: receptor of advanced glycation end
products; RAAS: renin-angiotensin-aldosterone system; TGF-?: transforming growth
factor-?; GFR: glomerular filtration rate
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2.2.9 Animal models of diabetic renal injury
Animal models of diabetic nephropathy are needed for studying the complex
pathogenic mechanisms, and possible strategies to prevent or treat diabetic
nephropathy. There are several murine models of diabetes. Most of the models
develop only mild or moderate renal abnormalities when compared to human diabetic
nephropathy, and no renal failure. The murine models are preferred to other animals,
because of lower costs, easier maintenance and the known genome. Porcine models
are also used for studying atherosclerosis, but they have not provided additional
benefits in regard of nephropathy (reviewed in (Hamamdzic, Wilensky 2013)).
2.2.9.1  Mouse models
Mouse models of diabetes include induction of diabetes by exogenous compounds,
naturally mutated mouse lines and transgenic or knockout mouse models. It has
become evident that the background strain of the mouse model is highly important for
the development of the renal injury, as the same genetic defects can cause variable
phenotypes in different mouse strains.
2.2.9.1.1 Diabetes induction by streptozotocin
Administration of streptozotocin by intraperitoneal injection to mice destroys
pancreatic ?-cells by acute necrosis or inflammatory reaction depending on the dose
(Tesch, Allen 2007, Like, Rossini 1976), and leads to insulinopenic diabetes. High
doses of streptozocin can also exert direct nephrotoxic effects and thus interfere with
the hyperglycaemia-induced renal disease (Tay et al. 2005). Streptozotocin treated
mice develop albuminuria and moderate mesangial expansion depending on the
backround strain (Gurley et al. 2006).
2.2.9.1.2  Spontaneously mutated mouse lines
Akita mouse
The Akita mice have a mutation in the insulin 2 gene, and develop pancreatic ?-cell
failure (Yoshioka et al. 1997). The Akita mouse was originally described to have a
modest renal phenotype in C57BL/6 strain (Gurley et al. 2010), but when the mice
were crossed to FVB/NJ background, they developed higher proteinuria and
mesangial expansion (Chang et al. 2012).
NOD mouse
Nonobese diabetic (NOD) mouse is a model of type 1 diabetes, developing
spontaneous autoimmune destruction of ?-cells and complete insulin deficiency
(Makino et al. 1980, Leiter, Prochazka & Coleman 1987). It is a good model for type
1 diabetes, but difficult for studying the diabetic complications, because diabetes
develops relatively late and at variable age. In addition, due to the complex genetics,
there is a lack of an appropriate control mouse line. The NOD mice have been
reported to develop seven-fold albuminuria when compared to the situation before the
onset of hyperglycaemia, as well as glomerular lesions (Doi et al. 1990).
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The db/db mouse
A recessive diabetes causing mutation in an inbred mouse strain was noticed in 1966,
and then named diabetes (db) (Hummel, Dickie & Coleman 1966). Later the diabetes
gene was found to encode the leptin receptor (Chen et al. 1996, Chua et al. 1996), and
to cause abnormal splicing of the protein (Lee et al. 1996). The db/db mouse is a
widely used and well characterized model of type 2 diabetes. The db/db mice are
hyperphagic, obese and insulin resistant. The degree of hyperglycaemia depends on
the backround strain (Hummel, Coleman & Lane 1972), and usually the C57BLKS/J
strain with high blood glucose is used. The db/db mice develop renal disease with
early rice in AER, and later mesangial expansion and GBM thickening (Sharma,
McCue & Dunn 2003a).
The ob/ob mouse
The obese gene in mouse (Ingalls, Dickie & Snell 1950) is due to a mutation in the
leptin gene (Zhang et al. 1994), and it causes a phenotype comparable to the db/db
mice. Also for ob/ob mouse the backround strain contributes to the severity of the
phenotype, and the model has originally been described to have mild renal changes.
However, when ob/ob mutation has been crossed to BTBR (black and tan brachyuric)
mouse to create a highly insulin resistant and hyperglycaemic mouse (Clee, Nadler &
Attie 2005), an early and severe kidney injury, characterised by progressive
glomerular lesions and podocyte loss, develops (Hudkins et al. 2010).
The Agouti-KK mouse
Both the Agouti mutation (Lu et al. 1994) and the genetic background of the KK
mouse line (Nakamura, Yamada 1967) predispose to insulin resistance, and when
crossed together (Iwatsuka, Shino & Suzuoki 1970)(Liao et al. 2003), have been
reported to induce albuminuria and glomerular changes (Liao et al. 2003).
2.2.9.1.3  Transgenic mouse models
OVE26 mouse
The OVE26 mouse is a transgenic mouse model, overexpressing calmodulin in
pancreatic ?-cells, which results in early-onset hypoinsulinemic diabetes (Epstein,
Overbeek & Means 1989). The OVE26 mice develop high albuminuria, and severe
glomerular pathology resembling human diabetic nephropathy (Zheng et al. 2004).
The phenotype is strain dependent, as demonstrated by crossing OVE26 mice from
FVB background to C57BL6 or to DBA2 strains, which significantly reduced
albuminuria and histological changes (Xu et al. 2010).
eNOS-/- / db/db mouse
Deletion of eNOS gene, and backcrossing the eNOS-/- mice to C57BLKS/J db/db
mice, substantially worsens the renal phenotype of the type 2 diabetic db/db mice
(Zhao et al. 2006). The eNOS-/- / db/db mice exhibit high albuminuria, mesangial
expansion and sclerosis, and even increase in serum creatinine levels, a feature rarely
captured by the mouse models of diabetes (Zhao et al. 2006).
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2.2.9.2  Rat models
2.2.9.2.1  Diabetes induction by streptozotocin
Diabetes can be induced by streptozotocin in rats, similarly as in mice, except that
usually single intravenous injection is used (Tesch, Allen 2007). In addition to normal
Sprague-Dawley and Wistar-Kyoto rats, streptozotocin-induced diabetes has been
studied in spontaneously hypertensive rats, and they have been reported to develop an
earlier rise in albumin excretion (Cooper et al. 1988).
2.2.9.2.2  Spontaneously mutated rat lines
Zucker rat
The obese Zucker rat (fa/fa-rat) corresponds to the db/db mouse model. It also has a
mutation in the leptin receptor gene (Chua et al. 1996), originally named as fatty gene
(Zucker & Zucker 1961). The renal injury, including proteinuria and glomerular
lesions, develops relatively late, although the reports are not totally consistent
(Kasiske et al. 1985, Coimbra et al. 2000).
Goto-Kakizaki rat
Goto-Kakizaki (GK) rat is an insulin resistant but nonobese polygenic model of type 2
diabetes (Goto et al. 1988) with defects in insulin secretion and hepatic metabolism
(Picarel-Blanchot et al. 1996). The renal phenotype is mild at the age of eight months
(Phillips et al. 2001), but glomerular changes are observed later, at the age of two
years (Sato, Komatsu & Kurumatani 2003), and the phenotype can be aggravated by
hypertension (Janssen et al. 2003). Interestingly, in one genetic loci associated with
glucose homeostasis in GK rats, a mutation was found in SHIP2 gene (Marion et al.
2002), the molecule investigated in our studies.
The OLETF rat
Otsuka Long-Evans Tokushima Fatty (OLETF) is a model of type 2 diabetes with
mild obesity and late-onset hyperglycaemia (Kawano et al. 1992), and multiple
genetic factors (Yamada et al. 2012). OLEFT rat has been reported to develop overt
proteinuria and nodular glomerular sclerosis (Kawano et al. 1992).
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2.3  Insulin signalling and insulin resistance
2.3.1  Mechanisms of insulin signalling and resistance
2.3.1.1  Insulin signalling pathways
Binding of insulin to its receptor on the cell surface starts a complex intracellular
signalling system (Figure 5). The insulin receptor is autophosphorylated on its
tyrosine residues, and the tyrosine kinase function of the activated receptor leads to
phosphorylation of insulin receptor substrate-1 (IRS-1) (Ullrich et al. 1985). The
effect of insulin on glucose uptake is mediated mainly through activation of
phosphoinositide 3-kinase (PI3K) causing in turn activation of protein kinase Akt and
translocation of glucose transporter GLUT4 containing vesicles to the plasma
membrane (Kanai et al. 1993, Hickey et al. 1997). The activation of the PI3K pathway
by insulin also promotes production of NO and vasodilatation (Steinberg et al. 1994).
The other intracellular insulin signalling pathway is the MAP kinase pathway, which
does not mediate the metabolic actions, but stimulates proliferation and production of
cytokines including the vasoconstrictor ET-1 (Boulton et al. 1991, Lazar et al. 1995,
Formoso et al. 2006).
Insulin signalling pathways are differentially regulated. In insulin resistant individuals
with obesity or type 2 diabetes, the phosphorylation of insulin receptor and IRS-1, and
the activation of the PI3K pathway are reduced in muscle (Cusi et al. 2000, Maegawa
et al. 1991), whereas the activity of the MAP kinase pathway is normal (Cusi et al.
2000). Thus, the stimulation of the MAP kinase pathway in hyperinsulinemic insulin
resistant diabetic patients can activate the adverse effects. Furthermore, MAP kinase
has been shown to downregulate the PI3K pathway by serine phosphorylation of IRS-
1 (De Fea, Roth 1997), and this function was induced by PKC that is known to be
activated by hyperglycaemia (De Fea, Roth 1997, Xia et al. 1994b). In addition, Ang
II has been reported to inhibit PI3K pathway but to activate MAP kinase pathway
(Andreozzi et al. 2004), linking RAAS to insulin resistance.
Negative regulators of the PI3K pathway include protein phosphatases that
dephosphorylate IRS-1 (Elchebly et al. 1999), and lipid phosphatases PTEN
(phosphatase and tensin homolog deleted on chromosome TEN) and SHIP2 (SH2-
domain-containing inositol polyphosphate 5-phosphatase 2) that hydrolyse the
PI(3,4,5,)trisphosphate produced by PI3K (Vinciguerra, Foti 2006).
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Figure 5. The effect of insulin on glucose uptake in muscle and adipose tissues is
mediated mainly through the PI3K pathway, leading to GLUT4 vesicle fusion to
plasma membrane. SHIP2 downregulates this signalling cascade by hydrolysing PIP3.
The activation of MAPK pathway mediates the mitogenic effects of insulin and
transcriptional regulation of various target genes. These pathways are differentially
regulated.
2.3.1.2  Mechanisms of insulin resistance
2.3.1.2.1 Glucotoxicity
Hyperglycaemia and consequent excess of intracellular glucose result in oxidative
stress (Brownlee 2001), and ROS induce insulin resistance (Houstis, Rosen & Lander
2006). In addition, AGEs, also resulting from hyperglycaemia, have been shown to
interfere with insulin response by impairing the PI3K-mediated insulin signalling
(Miele et al. 2003). In vitro studies have suggested that high glucose-induced insulin
resistance might be regulated by AMP-activated protein kinase (AMPK) (Tomas et al.
2002), and this can be explained by the regulation of Malonyl-CoA and DAG
concentrations by AMPK (Ruderman et al. 1999). Indeed, exercise activates AMPK
in muscle to favour fatty acid metabolism (Winder, Hardie 1996), and could thus
prevent insulin resistance.
2.3.1.2.2  Lipotoxicity
In insulin resistant state, free fatty acids (FFA) are released from the adipocytes, and
FFA concentration is increased in circulation (Golay, Chen & Reaven 1986).
Euglycaemic insulin clamp studies in rat (Griffin et al. 1999) and in healthy human
subjects (Roden et al. 1996, Belfort et al. 2005) have shown that increased FFA
further induce insulin resistance by inhibiting the insulin signalling cascade and
glucose uptake in muscle. In addition, elevated FFA levels are associated with an
increase in cellular DAG and activation of PKC and NF-?B pathways (Itani et al.
2002). Furthermore, increased fatty acid oxidation stimulates ROS formation
similarly like the excess of glucose (Inoguchi et al. 2000), subsequently leading to
increased inflammation.
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2.3.1.2.3  Adipose tissue inflammation and adipokines
The inflammation of adipose tissue plays crucial role in insulin resistance.
Transcriptional upregulation of inflammation and macrophage-related genes in
adipose tissue of high-fat diet-induced obese mice has been observed to precede the
elevation of plasma insulin level (Xu et al. 2003). In human patients with type 2
diabetes, markers of inflammation and endothelial dysfunction correlate with the
measures of insulin resistance and adiposity (Leinonen et al. 2003). In insulin
resistance and obesity, the adipose tissue also secretes inflammatory cytokines, e.g.
TNF-?, which has been shown to have an important role in further promoting
peripheral insulin resistance (Hotamisligil, Shargill & Spiegelman 1993). Also the
adipokines, leptin and adiponectin, are connected to the insulin resistance, which has
been shown by the studies where administration of these molecules improved insulin
sensitivity (Shimomura et al. 1999, Yamauchi et al. 2001).
2.3.2  The metabolic syndrome
Clustering of the clinical risk factors for cardiovascular disease, namely impaired
glucose tolerance or diabetes, central obesity, hypertension and dyslipidemia, is called
the metabolic syndrome. Various definitions of the metabolic syndrome have been
used, which makes comparison of different studies sometimes difficult. The latest
proposal for diagnostic criteria was published in 2009 as a joint statement of several
health organizations including the International Diabetes Federation (IDF) and the
American Heart Association (AHA), which previously had their own diagnostic
criteria for the metabolic syndrome (Alberti et al. 2009). This joint statement sets five
criteria: elevated waist circumference, elevated triglycerides, low high density
lipoprotein (HDL) cholesterol, elevated blood pressure and elevated fasting glucose.
If three criteria out of the five are fulfilled, a person is designated as having the
metabolic syndrome.
The common pathogenic factor for the components of the metabolic syndrome is
insulin resistance (Reviewed in (Kashyap, Defronzo 2007)). Insulin resistance is
essentially linked to obesity and glucose control. The dyslipidemia is caused by
insulin resistance through disturbed hepatic lipid metabolism in excess of FFA and
impaired PI3K signalling (Reviewed in (Avramoglu, Basciano & Adeli 2006)).
Insulin resistance is also associated with reduced lipoprotein lipase activity in
capillaries leading to impaired clearance of lipoprotein particles (Taskinen 1987). In
addition, insulin resistance is linked to hypertension and endothelial dysfunction by
the defects in the signalling leading to imbalance between NO and ET-1 as discussed
above.
2.3.3  The association between insulin resistance and diabetic nephropathy
Insulin resistance is known to be associated with microalbuminuria in patients with
both type 1 (Yip et al. 1993) and type 2 diabetes (Groop et al. 1993, Parvanova et al.
2006). Further, insulin resistance has been shown to precede and to predict the
development of both microalbuminuria and overt nephropathy in type 1 diabetes
(Orchard et al. 2002, Ekstrand, Groop & Gronhagen-Riska 1998). In addition, the
metabolic syndrome is a frequent phenomenon in patients with type 1 diabetes and
has been shown to be strongly associated with diabetic nephropathy (Thorn et al.
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2005). The exact mechanisms and causalities behind these associations have not been
solved. However, the hypothesis of insulin resistance as a pathogenic factor for
diabetic nephropathy is supported by the studies showing that the insulin sensitizing
agents thiazolidinediones have renoprotective effects in diabetic patients (Miyazaki et
al. 2007) and animal models (Zhang et al. 2008).
2.3.4  Insulin response in podocytes
Podocytes were found to be insulin-responsive cells and to increase their glucose
uptake after insulin stimulation (Coward et al. 2005). Insulin-induced glucose uptake
in cultured human podocytes is mediated by glucose transporters GLUT1 and GLUT4
(Coward et al. 2005), and the functional actin cytoskeleton and expression of nephrin
are essential in the process (Coward et al. 2005, Coward et al. 2007). GLUT2 and
GLUT4 mediated glucose uptake was also described in cultured rat podocytes (Lewko
et al. 2005). In addition, GLUT8 is expressed by podocytes, and is upregulated in
diabetic db/db mice (Schiffer et al. 2005). Upregulation of GLUT1 was also described
after exposing human podocytes to high glucose in vitro (Moutzouris et al. 2007). In
general, it can be assumed that the regulation of glucose transport is important for
diabetic complications, because they are largely due to the increase in the intracellular
glucose (Brownlee 2001). The results of GLUT1 overexpressing mice, are however,
somewhat confusing. Overexpression of GLUT1 in mesangial cells leads to
glomerular sclerosis (Wang et al. 2010), whereas overexpression of GLUT1 in
podocytes reduces mesangial expansion (Zhang et al. 2010).
Tejada et al. presented the first evidence of insulin resistance in podocytes (Tejada et
al. 2008). They isolated podocytes from diabetic db/db mice, and showed that db/db
podocytes were unable to phosphorylate Akt in response to insulin. In a resent study,
decreased Akt phosphorylation in response to insulin, was detected also in renal
cortex of heterozygous Akita mice (Drapeau et al. 2013). Akt has been recognised as
a survival factor in podocytes (Huber et al. 2003), and the decreased phosphorylation
of Akt was associated with increased apoptosis, when cultured db/db podocytes were
treated with TNF-? (Tejada et al. 2008). It was also found that C-jun N-terminal
kinase (JNK), a negative regulator of insulin signalling, was increased and activated
in glomeruli of db/db mice (Ijaz et al. 2009). However, when JNK was suppressed by
an inhibitory peptide or by genetic knockout, systemic insulin sensitivity improved,
but albuminuria increased (Ijaz et al. 2009). In cultured human podocytes, insulin
resistance was found to be induced by saturated free fatty acid palmitate (Lennon et
al. 2009a). In these experiments, insulin resistance was detected by reduced glucose
uptake and reduced phosphorylation of IRS-1 and Akt, and could be attenuated with
rosiglitazone treatment (Lennon et al. 2009a, Lennon et al. 2009b).
The strongest evidence for the importance of insulin signalling for podocyte function
comes from a transgenic mouse model with podocyte specific insulin receptor
knockout (Welsh et al. 2010). These mice develop albuminuria and mesangial
expansion and sclerosis. The study also demonstrated that insulin activates both PI3K
and MAP kinase pathways in podocytes in vivo and in vitro, and that insulin induces
reorganisation of the actin cytoskeleton in cultured podocytes (Welsh et al. 2010).
However, the role of insulin in maintaining the functional actin cytoskeleton podocyte
in vivo remains to be investigated.
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3 AIMS OF THE STUDY
Podocyte injury plays an important role in the development of diabetic nephropathy.
Insulin resistance has been associated with an increased risk for albuminuria in both
type 1 and type 2 diabetes, and podocytes have been shown to be insulin responsive
cells. However, it is not known if insulin resistance has a direct effect on podocyte
function.  This study aimed to investigate the role of CD2AP in podocyte injury, and
found a new interaction between CD2AP and lipid phosphatase SHIP2. Therefore, we
aimed to study the function of SHIP2 in the insulin response in podocytes, and to
investigate if polymorphisms in the genes coding for CD2AP and SHIP2 are
associated with diabetic nephropathy. The experiments aim to better understanding of
the pathophysiological mechanisms of diabetic nephropathy.
The specific aims were:
1. To characterise the interaction of CD2AP and SHIP2 and to study their role in
the regulation of insulin signalling in podocytes.
2. To investigate if polymorphisms in the INPPL1 gene, encoding SHIP2, are
associated with the metabolic syndrome and diabetic nephropathy in Finnish
patients with type 1 diabetes.
3. To investigate if polymorphisms in the CD2AP gene are associated with
diabetic nephropathy or ESRD in patients with type 1 diabetes.
4. To characterise the development of renal injury in the diabetic E1-DN mice.
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4  SUBJECTS, MATERIALS AND METHODS
4.1  Biochemical and cell culture experiments (Study I)
4.1.1 Yeast two-hybrid screening
The N-terminal part of mouse CD2AP cDNA (aa 1-330) was amplified by PCR and
subcloned into displayBAIT vector (Display System Biotech, Vista, CA, USA), that
was transformed into yeast strain EGY48 (Invitrogen, Carlsbad, CA, USA) together
with the green fluorescent protein containing displayREPORTER vector. The rat
glomerular yeast two-hybrid library (Takeda et al. 2001b)  in the displayTARGET
vector was transformed into yeast pretransformed with displayBAIT-CD2AP and
displayREPORTER vectors and plated on selective medium. Colonies expressing the
green fluorescent protein reporter were selected. Plasmid DNA of the positive clones
was electroporated into Escherichia coli KC8 (Clontech, Mountain View, CA, USA)
and the inserts were analyzed by sequencing.
4.1.2 Cell culture
Immortalized human podocyte cell line (Saleem et al. 2002) was maintained in RPMI
medium, supplemented with 10% FBS, and insulin, transferrin and selenite (ITS) at +
33 ?C, and transferred to + 37 ?C for differentiation for 14 days. HIRc cells (rat
fibroblasts overexpressing human insulin receptor) (McClain et al. 1987) were
maintained in DMEM medium, supplemented with 10% FBS, ultraglutamine,
penicillin and streptomycin. For high-glucose treatment, human podocytes were
cultured at + 37 ?C for 14 days in RPMI medium containing 30 mM glucose, or
mannitol resulting in the same osmolality as a control.  All cell culture reagents were
from Sigma (St. Louis, MO, USA) except ultraglutamine from Lonza (Basel,
Switzerland).
4.1.2.1  Transfections and infections
Human SHIP2 cDNA with HA-tag in pCGN vector (Dyson et al. 2001) or empty
pCGN were transfected into proliferating human podocytes using Lipofectamine 2000
reagent (Invitrogen), and used for experiments 48 h after transfection. The lentiviral
vector pSIN18.cppt.hEF1?p.WPRE (Gropp et al. 2003) was used to overexpress
SHIP2 in differentiated podocytes. Viruses were produced with KS pCMV?8.9 and
pHCMV packaging plasmids in HEK 293FT cells. The viruses were added to
differentiated podocytes on day 11 or 12 of differentiation, and podocytes were
incubated at +37 °C for 10 min, followed by centrifugation 1360 x g  at +4 °C for 30
min. Virus-containing medium was replaced with regular medium after  10-12 hours.
4.1.2.2  Insulin stimulation
Proliferating podocytes expressing SHIP2-pCGN or empty pCGN were serum and
ITS starved overnight (18-20 h) and stimulated with 200 nM insulin for 15 min. Akt
phosphorylation was measured by immunoblotting with Phospho-Akt (Ser473)
antibody (Cell Signaling Technology, Danvers, MA, USA) recognizing Akt1
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phosphorylated at Ser473, and Akt2 and Akt3 phosphorylated at corresponding
residues, and compared to total Akt level detected with Pan Akt antibody (R&D
Systems, Minneapolis, MN, USA). An ELISA-based Akt/PKB Kinase Activity Assay
Kit (Assay Designs, Enzo Biochem, New York, NY, USA) was used to measure Akt
kinase activity.
4.1.3  Immunoblotting
Cells were lysed into ice-cold 1% NP-40, 20 mM Hepes, pH 7.5, 150 mM NaCl with
1x Complete™ EDTA-free proteinase inhibitor cocktail (Roche, Basel, Switzerland),
50 mM NaF and 1 mM Na3VO4. Glomeruli and tubuli were isolated from rat kidney
cortex by sieving and lysed in the same lysis buffer. Proteins were separated by SDS-
PAGE and transferred to PVDF-FL membranes (Millipore, Billerica, MA, USA),
blocked with Odyssey blocking buffer (LI-COR, Lincoln, NE, USA), and incubated
with anti-SHIP2 I-20 (Santa-Cruz Biotechnology, Santa-Cruz, CA, USA), anti-
CD2AP 1774 or 1764 (Lehtonen et al. 2000b), anti-phospho-Akt (Ser473) (Cell
Signaling), anti-Pan Akt (R&D Systems), anti-phosphotyrosine PT-66 (Sigma) or
anti-actin (Sigma), followed by Alexa Fluor 680 (Invitrogen) or IRDye 800 (LI-COR)
secondary antibodies, and detected and quantitated with an Odyssey Infrared Imager
(LI-COR).
4.1.4  Pull-down assay
The glutathione-S-transferase (GST)-tag fusion protein constructs of mouse CD2AP
SH3 domains were generated as previously described (Palmen et al. 2002). The N-
terminal part of mouse CD2AP (aa 1-330) was subcloned into pGEX-4T-1 vector
(Amersham Biosciences, Buckinghamshire, UK) to produce GST-CD2AP-N. GST-
CD2AP fusion proteins were produced in E. coli BL21(DE3) (Stratagene; La Jolla,
CA, USA), and purified on glutathione-Sepharose beads (Amersham Biosciences).
Cell and glomerular lysates were incubated with glutathione-Sepharose beads at 4°C
for 1 h, followed by incubation at 4°C for 4 h with GST-CD2AP fusion proteins or
GST on beads. Beads were washed with lysis buffer, boiled in Laemmli sample buffer
and proteins were separated by SDS-PAGE for immunoblotting with anti-SHIP2 I-20.
4.1.5  Immunoprecipitation
HIRc cells were lysed from basal state, from 16 hours starvation, or from 16 hours
starvation followed by stimulation with 17 nM insulin for 7 minutes. Lysates were
incubated with protein A-Sepharose beads (Invitrogen) or TrueBlot anti-goat Ig IP
Beads (eBioscience, San Diego, CA, USA) at 4°C for 1 h, followed by incubation
with CD2AP 1764 antibody (Lehtonen et al. 2000a)  or normal rabbit serum for 16-20
h at 4°C, or alternatively, with SHIP2 I-20 antibody or goat IgG. Protein complexes
were bound to protein A-Sepharose or goat TrueBlot beads at 4°C for 1 h, washed,
and boiled in Laemmli sample buffer for immunoblotting with anti-SHIP2 I-20, anti-
CD2AP 1764, or anti-phosphotyrosine.
4.1.6  Immunofluorescence staining
Differentiated podocytes were stimulated with 200 nM insulin (Actrapid, Novo
Nordisk, Denmark) for 5 or 15 min after starvation for 14 hours, fixed with 4%
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paraformaldehyde, permeabilized with 0.1% Triton X-100 and blocked with CAS-
block (Zymed, South San Francisco, CA, USA). Cells were incubated with SHIP2
C76A7 (Cell Signalling) or CD2AP H-290 (Santa-Cruz) primary antibodies in
ChemMate (Dako, Glostrup, Denmark) for 1 h, followed by Alexa Fluor 555
(Invitrogen) donkey anti-rabbit secondary antibody for 1 h. After mounting in Moviol,
cells were examined with a Zeiss Axiophot 2 microscope.
4.1.7  Fluorescence-activated cell sorting
SHIP2 was overexpressed in differentiated podocytes by lentiviral infection as
described above, and 48 hours later apoptosis was measured by fluorescence-activated
cell sorting (FACS) using Annexin V-FITC Apoptosis Kit (Pharmingen, BD, Franklin
Lakes, NJ, USA) and double staining with 7-Aminoactinomycin D (7-AAD) (BD).
Trypsinised cells were combined with detached cells from media, centrifuged, and
resuspended in Annexin V Binding Buffer (BD) containing Annexin V-FITC and 7-
AAD. After 15 min incubation and washes, cells were fixed with 4%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA), washed, and
analyzed for apoptosis using FACSAria (BD). Cells positive for Annexin V-FITC and
negative for 7-AAD were regarded as apoptotic, positive for both as late apoptotic,
positive for 7-AAD and negative for Annexin V-FITC as necrotic, and negative for
both as viable.
4.2  Animal studies (Studies I and IV)
4.2.1  Animals
SHIP2 expression was studied in male Sprague-Dawley rats and male FVB mice.
Male db/db mice and heterozygous db/+ controls in C57BLKS background (BKS.Cg-
m+/+Leprdb/BomTac) were from Taconic Europe (Ry, Denmark), and obese (fa/fa)
and lean (fa/+) Zucker rats (Crl:ZUC-Leprfa) from Charles River Laboratories
(Sulzfeld, Germany). The generation of the E1-DN mice in FVB background has been
described previously (Miettinen et al. 2006). The transgene was composed of a human
kinase-deficient EGF-R cDNA, a myc tag and a growth hormone polyA tail under
mouse Pdx-1 promoter (Miettinen et al. 2006). Male E1-DN mice were studied, and
male wild-type littermates were used as controls. Kidney samples were also collected
from non-littermate male mice of the FVB strain in the same animal facility. Animal
care followed the principles of laboratory animal care and Finnish laws, and the
experiments were approved by the National Animal Experiment Board.
4.2.2 Blood glucose and urine albumin measurements
Blood glucose was measured as random fed values from tail vein samples using
OneTouch Ultra glucometer (Lifescan, Milpitas, CA, USA). Urine was collected as
24 hour samples in metabolic cages, or as spot urine samples. Urine albumin
concentration was analysed with mouse or rat albumin ELISA kit (CellTrend,
Luckenwalde, Germany). Urine creatinine was measured using CREA plus enzymatic
assay (Roche), to determine the urinary albumin to creatinine ratio from the spot urine
samples.
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4.2.3  Histology
For histological analysis kidneys were fixed in 10% formalin, dehydrated and
embedded in paraffin. Sections (5 ?m) were deparaffinised, stained with Periodic
acid-Schiff (PAS) or haematoxylin-eosin using standard procedures. The PAS signal
quantitation was performed with the FIJI image analysis software. The color of PAS
staining was defined and the signal intensity measured in glomerular tuft, and the
resulting PAS staining intensity was divided by the glomerular surface area.
4.2.4  Immunohistochemistry
Immunoperoxidase staining was performed with a VectaStain Elite kit (Vector
Laboratories, Burlingame, CA, USA). Sections were deparaffinized, boiled in 10 mM
citric acid (pH 6.0) for 15 min for antigen retrieval, incubated in 0.5% H2O2 in
methanol for 30 min for endogenous peroxidase inactivation, and blocked with CAS-
block (Zymed). Primary antibodies for activated Caspase-3 (Cleaved Caspase-3,
Asp175; Cell Signaling), Ki-67 (Bethyl Laboratories, Montgomery, TX, USA),
SHIP2 (I-20; Santa-Cruz) and CD2AP 1774 were used, followed by incubation with
biotinylated rabbit anti-goat or goat anti-rabbit secondary antibody, and by incubation
with ABC-reagent and AEC colour reagent (Sigma). Sections were counterstained
with haematoxylin, mounted with Shandon Immu-Mount (Thermo Scientific,
Waltham, MA) and examined with a Nikon Eclipse 800 microscope. For
immunofluorescence stainings, frozen kidney sections (5µm) were fixed with ice-cold
acetone for 10 minutes, washed and blocked with CAS-block (Zymed). Sections were
incubated with primary antibodies for nephrin (GP-N2; Progen Biotechnik GmbH,
Heidelberg, Germany), podocin (Sigma), CD2AP (1774; (Lehtonen et al. 2000a)) or
ZO-1 (Zymed) diluted in ChemMate (Dako), followed by Alexafluor 555-conjugated
secondary antibodies (Invitrogen). Sections were mounted in Moviol or Vectashield
Mounting Medium (Vector Laboratories), and analysed using Zeiss Axiophot 2
microscope or Leica SP2 confocal microscope. The expression level of nephrin was
quantified from confocal images by FIJI image analysis software by measuring the
staining intensity of nephrin from the glomerular tuft and dividing the intensity by the
glomerular surface area.
4.2.5  Electron microscopy
Cortical kidney samples were fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer
(pH 7.2-7.4) at room temperature for 2 h, postfixed in 1% osmium tetroxide for 2 h,
stained en-bloc in 1% uranyl acetate in 10% ethanol for 1h, dehydrated and embedded
in Epon. Uranyl acetate and lead citrate stained thin sections were examined with a
JEM-1400 Transmission Electron Microscope equipped with Olympus-SIS Morada
digital camera. GBM thickness was measured with the FIJI software.
4.2.6  Statistics
Significance of the differences between the groups was evaluated by Student’s
unpaired t-test for normally distributed variables and by Mann-Whitney U-test for
non-normally distributed variables. P< 0.05 was set as the limit for statistical
significance. Analyses were performed using SPSS PASW Statistics (version 18)
(IBM, Armonk, NY, USA) or Excel (Microsoft, Redmond, WA, USA) softwares.
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4.3  Genetic studies (Studies II and III)
4.3.1  Subjects
4.3.1.1  FinnDiane patients and data collection
The genetic studies were part of the Finnish Diabetic Nephropathy Study (FinnDiane),
an ongoing nationwide multicenter study for diabetic complications. The study
protocol has been approved by the ethics committees of all participating centres and
follows the principles of the Declaration of Helsinki. Written informed consent was
given by all study subjects.
The clinical data and medical history were obtained with standardized questionnaire
filled by the patient’s attending physician. The data included e.g. current medication,
history of smoking, cardiovascular disease and other diabetic complications. Weight,
height and waist and hip circumferences were measured. Blood pressure was
measured twice in the sitting position after a 10 minutes rest, and the mean values of
these two measurements were calculated for systolic and diastolic blood pressure.
Blood samples were collected, and DNA extracted by standard assays. Serum HDL
and triglyceride concentrations were measured from fasting samples at the research
laboratory of the Helsinki University Central Hospital, Division of Cardiology, with
enzymatic methods using a HTS 7000 Plus assay reader (Perkin Elmer, Wellesley,
MA, USA) and Cobas Mira autoanalyzer (ABX Diagnostics, Montpellier, France),
respectively. HbA1c was determined at each centre by standardized assays. Serum
creatinine was measured centrally with the isotope dilution-mass spectrometry
(IDMS) traceable enzymatic method or with the Jaffé method, and a conversion
formula (Creatinine [IDMS] = [0.953 x Creatinine Jaffé] - 7.261) was used. Estimated
glomerular filtration rate (eGFR) was calculated with the CKD-EPI formula (Levey et
al. 2009).
Urine samples were collected as timed overnight or 24-hour urine samples. Urinary
albumin concentration was determined by radioimmunoassay using a LKB Wallac
RiaGamma counter (Pharmacia, Uppsala, Sweden) or by an immunoturbimetric
method using a Hitachi 911 analyzer (Roche).
To perform the time to ESRD analysis, longitudinal follow-up data from the
FinnDiane collection was used. The latest data for ESRD were obtained from the
Finnish Hospital Discharge Registry (HILMO), and the mortality data for the
competing risk analysis were retrieved from the Finnish Death Registry.
4.3.1.2  Phenotype definitions
All patients included in the analyses had type 1 diabetes, that was defined as an age of
onset <35 years and permanent insulin treatment started within 1 year of diagnosis.
History of smoking was defined as smoking at least 1 cigarette per day for one year.
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The nephropathy status of the patients was determined based on their urinary albumin
excretion rate (AER) in two out of three consecutive overnight or 24 h urine
collections. Normal urinary albumin excretion was defined as an AER <20 ?g/min or
<30 mg/24 h, microalbuminuria as an AER ?20<200 ?g/min or ?30<300 mg/24 h,
macroalbuminuria as an AER ?200 ?g/min or ?300 mg/24 h, and end stage renal
disease (ESRD) as the patient being on dialysis or having received a kidney transplant.
Patients with macroalbuminuria or ESRD were classified as cases with diabetic
nephropathy, while control subjects were required to have a normal AER after at least
15 years of diabetes duration. The individuals with microalbuminuria were excluded
from the analysis regarding diabetic nephropathy. In the analysis regarding ESRD,
patients with ESRD were compared to all other groups.
The metabolic syndrome was defined using the most recent criteria (Alberti et al.
2009). The patient was classified as having the metabolic syndrome if three criteria out
of five were fulfilled. The five criteria were: waist circumference ? 94 cm for men and
?80 cm for women (European thresholds), triglycerides ? 1.7 mmol/l, HDL cholesterol
<1.0 mmol/l for men and <1.3 mmol/l for women, blood pressure ?130 mmHg systolic
and/or ?85 mmHg diastolic or antihypertensive medication and a history of
hypertension, and elevated fasting glucose. All participants in the study were
considered to fulfil the criteria for elevated fasting glucose due to their type 1 diabetes.
4.3.1.3  Replications cohorts
Replication cohorts consisted of patients with type 1 diabetes from Denmark (Steno
Diabetes Center), from the UK and Republic of Ireland (Warren 3/Genetics of Kidneys
in Diabetes UK and All-Ireland collections [UK-ROI]) and from Italy (Complications
of Diabetes Unit of the San Raffaele Scientific Institute, Milan). Danish patients were
classified similarly as FinnDiane patients into groups with normal AER,
microalbuminuria, macroalbuminuria or ESRD. The UK-ROI collection, as previously
described (McKnight et al. 2009), and the Italian collection did not include patients
with microalbuminuria, and they were divided into groups with normal AER,
macroalbuminuria, or ESRD.
4.3.2  Selection of SNPs and genotyping
Single-nucleotide polymorphisms (SNPs) with minor allele frequency >0.05 in the
CEU population (Utah residents with Northern and Western European ancestry) were
selected from the HapMap database (http://hapmap.ncbi.nlm.nih.gov/) (Public
Release 23a or 24), to cover the INPPL1 and CD2AP genes +/- 20 kb. Nine tagSNPs
for INPPL1 and 18 tagSNPs for CD2AP were found to capture all SNPs in the regions
with r2 > 0.8 (pairwise tagging) by using the Tagger program in the Haploview
software (version 4.2) (Barrett 2009, de Bakker et al. 2005). Genotyping was
performed with ABI Prism 7900 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) or with Sequenom’s MassARRAY iPLEX system (Sequenom,
San Diego, CA, USA). Genotyping accuracy was ensured by using 2% duplicated
internal controls in each run, and these were 100% coherent. Patients with <50% of
the SNPs successfully genotyped were removed from the analysis (n=11 for INPPL1
and n=21 for CD2AP). All the 9 tagSNPs for INPPL, and 15 out of the 18 tagSNPs
for CD2AP were successfully genotyped. Two CD2AP SNPs were left out because of
genotyping problems, and one SNP was out of Hardy-Weinberg equilibrium (HWE).
After these exclusions, genotyping success rate was >97% for each remaining SNP,
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and genotype distributions were in HWE (p > 0.01). Two CD2AP SNPs had a minor
allele frequency below 5% in the Finnish population, and they were excluded from the
statistical analysis.
Three CD2AP SNPs were selected for replication. Danish and Italian patients were
genotyped using the ABI Prism 7900 Sequence Detection System (Applied
Biosystems), reaching genotyping success rate >95% for the Italian patients and
>98% for the Danish patients. In the UK-ROI cohort, one SNP was genotyped with
the same method, and for two other SNPs, tagSNPs genotyped using Sequenom
iPLEX Gold assays, were used. The UK-ROI genotyping success rate was >99%.
4.3.3  Power calculations
A relative risk of 1.4 was assumed for diabetic nephropathy, ESRD and the metabolic
syndrome. Prevalence estimations of 30% for diabetic nephropathy, 10% for ESRD and
50% for the metabolic syndrome were used. Recessive model of inheritance was
applied for INPPL1, and additive genotypic model for CD2AP. For INPPL1, the power
calculated with minor allele frequencies 0.05, 0.25 and 0.40, was 0.07, 0.67 and 0.95 (P
= 0.05), respectively, for diabetic nephropathy, using a sample size of 784 patients and
946 controls, and 0.12, 0.99 and 1 (P = 0.05) for the metabolic syndrome with a sample
size of 1328 patients and 1074 controls. For CD2AP, the power with minor allele
frequencies 0.05, 0.25 and 0.40, was 0.08, 0.70 and 0.96 (p=0.05), respectively, for
diabetic nephropathy, using a sample size of 787 patients and 1050 controls, and 0.06,
0.28 and 0.54 (p=0.05) for ESRD with a sample size of 264 patients and 1987 controls.
Power was calculated with the Genetic Power Calculator (Purcell, Cherny & Sham
2003) (http://pngu.mgh.harvard.edu/~purcell/gpc/).
4.3.4  Statistics
For the cross-sectional case-control association analyses, genotype and allele
frequencies were compared between cases and controls with the ?2 test. Binary logistic
regression models with covariates were used to test the SNPs in recessive or additive
genotypic models. Differences in continuous variables between the genotypes were
evaluated with ANOVA or linear regression. The association analyses were performed
with PASW Statistics (version 18) (IBM, Armonk, NY, USA) and with PLINK
(version 1.07) (Purcell et al. 2007) (http://pngu.mgh.harvard.edu/~purcell/plink/). The
Haploview program (version 4.2) (Barrett 2009) was used to estimate the haplotypes in
INPPL1 and CD2AP genes and their association with the metabolic syndrome or
ESRD. Cox regression analysis and competing risk analysis were conducted using the
‘survival’ or ‘cmprsk’ packages, respectively, in R software (version 2.36-10)
(http://cran.r-project.org/). The meta-analysis was performed with PLINK, and fixed-
effects model was used.
44
5  RESULTS
5.1 Study I - Lipid phosphatase SHIP2 downregulates insulin
signalling in podocytes
5.1.1  CD2AP interacts with SHIP2 in glomeruli
In order to study the role of the adaptor protein CD2AP in podocyte injury, a yeast-
two-hybrid screening of a rat glomerular library was performed. Interestingly, CD2AP
was found to bind to SHIP2, a negative regulator of  PI3K-mediated insulin signalling
(Dyson et al. 2005), that was known to function in liver, muscle and adipose cells, but
its role in the kidney had not been studied previously. To confirm the expression of
SHIP2 in glomeruli, rat glomerular and tubular lysates were isolated by the sieving
technique and immunoblotted with SHIP2 antibodies, showing that SHIP2 is
expressed in both glomeruli and tubuli in the kidney (Study I, Fig.1A). To more
precisely localise SHIP2 in glomeruli, immunoperoxidase stainings of mouse kidney
sections were performed (Study I, Fig.1B). Staining of adjacent sections for SHIP2
and podocyte marker CD2AP confirmed the expression of SHIP2 in podocytes (Study
I, Fig.1C-D).
The yeast two-hybrid screening identified the COOH-terminal region of SHIP2 to
bind CD2AP. This region contains a proline-rich domain, known to mediate
interactions with SH3 domains. The NH2-terminus of CD2AP contains three SH3
protein-protein interaction domains. To map which of the SH3-domains of CD2AP
mediates the interaction with SHIP2, pull-down assays with GST-CD2AP-SH3-
domains and the GST-CD2AP-NH2-terminus were performed on cultured human
podocytes and rat glomerular lysates. The result of the pull-down experiment
indicated that the binding is primarily mediated by the 3rd SH3-domain of CD2AP and
confirmed the interaction between SHIP2 and CD2AP in glomeruli (Study I, Fig.2A-
B).
To confirm the intracellular interaction between CD2AP and SHIP2, a co-
immunoprecipitation assay was conducted, showing that CD2AP antibodies co-
immunoprecipitated SHIP2 from HIRc cells (Study I, Fig.2C). The interaction was
not dependent on insulin stimulation, as the interaction was observed in basal state,
starved and insulin stimulated cells. Two different size bands of SHIP2 were detected
in the cell lysate, and only the lower one was precipitated by CD2AP. Interestingly,
only the upper band of SHIP2 is phosphorylated, as shown by immunoprecipitation
with SHIP2 antibodies followed by immunoblotting the precipitate with anti-SHIP2
and anti-phosphotyrosine antibodies (Study I, Fig.2D). This result indicated that
CD2AP binds to SHIP2 in its non-tyrosine phosphorylated form.
5.1.2  Effects of insulin and high glucose on SHIP2 expression and localisation in
cultured podocytes
Endogenous SHIP2 was located predominantly in the cytoplasm in basal and starved
state in differentiated podocytes, but after insulin stimulation it was partly
translocated to plasma membrane (Study I, Fig.3). CD2AP was localised in cytoplasm
and the localisation did not change after insulin stimulation. To study the effect of
high glucose environment on SHIP2 expression, podocytes were differentiated for
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two weeks in cell culture medium with a glucose concentration of 30 mmol/l, or
mannitol as an osmotic control. SHIP2 was expressed at equal levels in both
conditions, and also the Akt phosphorylation response to insulin was similar, proving
that SHIP2 expression level is not controlled by glucose concentration, at least in an
in vitro situation (Study I, Fig.9).
5.1.3  Overexpression of SHIP2 downregulates insulin signalling and promotes
apoptosis in cultured podocytes
The function of SHIP2 in the regulation of insulin-activated PI3K signalling pathway
was studied by measuring the phosphorylation and activation of Akt protein kinase in
SHIP2 overexpressing cultured podocytes. In unstimulated cells the phosphorylation
level of Akt was similar between SHIP2 overexpressing cells and control cells
transfected with an empty vector, but when podocytes were stimulated with insulin,
Akt phosphorylation level remained 16% lower in SHIP2 overexpressing cells (Study
I, Fig.4). In addition to measuring Akt phosphorylation by immunoblotting, Akt
activation was detected with an ELISA-based Akt activity assay. The ELISA-assay
showed that in control cells Akt kinase activity was increased by 32% by insulin
stimulation, but in SHIP2 overexpressing podocytes Akt activity was even lower after
insulin stimulation when compared to starved state. The difference in Akt activity
after insulin stimulation between SHIP2 overexpressing and control podocytes was
35% (p=0.02, Student’s t-test) (Study I, Fig.5). The results on Akt phosphorylation
and activity indicate that SHIP2 downregulates the PI3K-mediated insulin signalling
pathway in podocytes. Since Akt activation is known to act as a survival signal in
podocytes, the effect of SHIP2 overexpression on apoptosis was studied using
differentiated podocytes. When SHIP2 was overexpressed by lentiviral infection and
apoptosis measured by FACS, the proportion of apoptotic cells increased to 8.6%
compared to 4.5% in control podocytes, infected with empty vector (Study I, Fig.6).
The proportion of necrotic cells was not affected by SHIP2 overexpression.
5.1.4  SHIP2 is upregulated in glomeruli of diabetic rats and mice
The expression of SHIP2 was studied in glomeruli of obese Zucker rats, an animal
model of insulin resistance. Kidneys were analysed from three obese and three lean
rats at 12 weeks of age, and six obese and six lean rats at older age of 40 weeks. At 40
weeks of age the obese rats had proteinuria, determined by urine albumin to creatinine
ratio. They also had slightly higher weights and blood glucose levels than the
controls, but these differences were not statistically significant. The expression of
SHIP2 was found to be increased in glomeruli of the obese Zucker rats when
compared to the lean controls? at both ages (p<0.05, Student’s t-test) (Study I, Fig.7),
whereas in tubuli SHIP2 was expressed at equal levels. Diabetic db/db mice were
used as another model of insulin resistant animals. These mice were clearly obese,
hyperglycaemic and proteinuric at the age of 8 weeks compared to heterozygous db/+
controls. The level of SHIP2 expression in immunoperoxidase stained kidney sections
was rated visually by two independent researchers blinded from the genotypes.
Analysis of eight randomly chosen glomeruli from six db/db and six db/+ mice
showed a trend of higher expression of SHIP2 in podocytes in diabetic db/db mice,
but there was some variation between individual mice and the difference did not reach
statistical significance (p=0.059, Students’s t-test) (Study I, Fig.8).
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5.2 Study II  - INPPL1 is associated with the metabolic syndrome in
male patients with type 1 diabetes, but not with diabetic nephropathy
The INPPL1 gene polymorphisms have been previously found to be associated with
the components of the metabolic syndrome in a British cohort (Kaisaki et al. 2004).
Since the metabolic syndrome is a common feature in patients with type 1 diabetes,
and a risk factor for diabetic nephropathy (Thorn et al. 2005), this study aimed to
investigate if polymorphisms in the INPPL1 gene are associated with the metabolic
syndrome and diabetic nephropathy in Finnish individuals with type 1 diabetes.
Altogether 2526 patients with type 1 diabetes were genotyped, and 2402 individuals
with appropriate phenotypic data available were included in the analysis regarding the
metabolic syndrome. From the analysis regarding diabetic nephropathy, the
individuals with microalbuminuria were excluded, resulting in 1730 patients.
The patients were divided into groups according to their diabetic nephropathy status
and the presence or absence of the metabolic syndrome (Table 1). Diabetic
nephropathy was more frequent in individuals with the metabolic syndrome than in
those without, and accordingly, the metabolic syndrome was detected more often in
patients with diabetic nephropathy than in controls. The prevalence of the metabolic
syndrome did not differ between the sexes, but diabetic nephropathy was more
common in men than in women. The association between diabetic nephropathy and
the metabolic syndrome persisted within both sexes. History of smoking was
associated with both phenotypes.
Nine SNPs covering the INPPL1 gene were genotyped, and the genotype and allele
frequencies were compared between the groups. The homozygous genotype for the
minor allele of the SNP rs2276048 was found to be protective for the metabolic
syndrome with an OR of 0.55 (95% CI 0.36-0.83), p = 0.005. Also two other SNPs,
rs2276047 and rs10751199, were suggestively associated with the metabolic
syndrome in the recessive genotypic model (Table 2). Genotype or allele frequencies
of the nine genotyped SNPs did not differ between the individuals with or without
diabetic nephropathy.
When the association analyses were performed separately for both sexes, the
associations were found to be clearly sex-dependent. When only men were analysed,
the rs2276048, rs2276047 and rs10751199 were associated with the metabolic
syndrome with ORs 0.23 (95% CI 0.11-0.45), 0.37 (0.21-0.65) and 0.45 (0.27-0.74),
and P-values 2.1 x 10-5, 0.001 and 0.002, respectively, in the recessive genotypic
model, adjusted for age, sex, diabetes duration and history of smoking (Table 2). In
women, no statistically significant associations were found. The interaction terms
between rs2276048 and rs2276047 and sex were significant, with p-values of 0.0003
and 0.006.
The haplotype composition showed that the two significant SNPs, rs2276048 and
rs2276047, were in the same haplotype block with an r2 value of 0.89. When the
estimated haplotype frequencies within the haplotype blocks were compared in all
individuals, or men and women separately, no significant associations with the
metabolic syndrome were revealed.
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Genotypes of the SNPs rs2276048, rs2276047 and rs10751199 were also analysed for
association with the different components of the metabolic syndrome separately.
Interestingly, there was a linear trend, although not statistically significant, towards
lower blood pressure and waist circumference in carriers of the minor alleles. No
associations with renal variables (creatinine, AER, eGFR) were found with the SNPs.
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5.3  Study III  - CD2AP is associated with end stage renal disease in
patients with type 1 diabetes
As the adaptor protein CD2AP is essential for podocyte function, we hypothesised
that variations in the CD2AP gene can influence susceptibility to glomerular injury in
diabetes and investigated if polymorphisms in the CD2AP gene are associated with
diabetic nephropathy and ESRD.
The discovery cohort, consisting of 2251 Finnish patients with type 1 diabetes, was
divided into groups according to patients’ nephropathy status. There were 1050
control patients with normal AER and at least 15 years diabetes duration, 414 patients
with microalbuminuria, 523 with macroalbuminuria and 264 with ESRD (The main
characteristics of the patients are shown in Table 3). Comparison of allele and
genotype frequencies of the 13 SNPs in the CD2AP gene between patients with
diabetic nephropathy and controls, revealed no associations. Interestingly, when
patients with ESRD were compared to all other groups, three CD2AP SNPs,
rs9369717, rs6936632 and rs9349417, were found to be associated with ESRD in the
allelic model, with ORs of 1.40 (1.14-1.73), 1.36 (1.06-1.76) and 1.41 (1.14-1.73),
and p-values of 0.002, 0.015 and 0.001, respectively (Table 4). In addition, when
these three SNPs were tested for association with AER and eGFR as continuous
variables, an association between rs9369717 and eGFR was detected (beta -2.9 [-5.3, -
0.6], p=0.015), but no associations with AER were found. Transplanted patients were
excluded from quantitative trait analyses. The haplotype analysis, comparing
estimated haplotype frequencies within two haplotype blocks between patients with or
without ESRD, showed a suggestive association for haplotype GGAGAGTG in the
block 1 (p=0.022) (Figure 6). The two most significant SNPs in the allelic and
genotypic analysis, rs9369717 and rs9349417, were in strong linkage disequilibrium
(LD) with an r2 value of 0.98 (Figure 6).
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Figure 6. The figure shows the exon-intron structure of the CD2AP gene, indicated
by the arrow above. The vertical lines represent the exons. The location of the
genotyped SNPs in the gene is shown in the lower figure. The three significant SNPs
are highlighted with the boxes. The linkage disequilibrium plot shows the r2 values
between each pair of the SNPs.
To analyse if SNPs rs9369717, rs6936632 and rs9349417 are associated with the
development rate of ESRD, a Cox regression analysis was performed. When all
patients were taken into the analysis, the SNP rs9349417 was found to be associated
with faster development of ESRD (Hazard ratio 1.17, p=0.049), and when only ESRD
patients were included, the SNP rs9369717 was associated with the ESRD development
rate (Hazard ratio 1.17, p=0.035) (Study III, Fig.1). No significant differences in time
to ESRD were found with the SNP rs6936632. The question of possible survival bias in
ESRD patients, due to the largely increased risk of death for patients with diabetic
nephropathy, was addressed with a competing risk analysis. When the risks of ESRD
and death were compared between the genotypes in relation to time from the onset of
diabetes, the SNP rs9349417 was associated with the predicted cumulative incidence of
ESRD, but none of the SNPs was associated with the risk of death (Study III, Fig.2).
The three CD2AP SNPs, that were found to be associated with ESRD in Finnish
patients, were selected for replication in three additional European populations (Table
3). All the three SNPs were genotyped in individuals with type 1 diabetes from
Denmark and Italy, and rs6936632 from United Kingdom and Republic of Ireland
(UK-ROI). TagSNPs rs9296567 and rs9296564 were used instead of rs9369717 and
rs9349417 for UK-ROI patients. None of the SNPs was significant within the
replication cohorts separately, but in the Danish cohort, a trend towards a higher
minor allele frequency in ESRD patients was seen for all three SNPs. In addition,
meta-analysis of the three populations revealed significant associations of rs9369717
and rs9349417 with ESRD (Figure 7). The third SNP, rs6936632, was associated with
ESRD in the meta-analysis of the four populations, but this result did not remain
significant after correction for multiple testing (Figure 7).
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Figure 7. Forest plot showing the ORs for ESRD with minor allele of the SNPs in the
genotypic association model, adjusted for sex, age and diabetes duration, in the
cohorts separately and in the meta-analysis. For SNP rs6936632, the summary of all
the cohorts is shown, as the data was available. For SNPs rs9369717 and rs9349417
three cohorts were available for the meta-analysis, and tagSNPs from UK-ROI cohort
are shown separately.
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5.4  Study IV - Early-onset diabetic E1-DN mice develop albuminuria
and glomerular injury
5.4.1  Diabetic E1-DN mice develop albuminuria
The transgenic mice expressing kinase-negative epidermal growth factor receptor
(EGF-R) under the pancreatic duodenal homeobox-1 (pdx-1) promoter (E1-DN mice)
are diabetic due to impaired postnatal growth of ?-cell mass and subsequent reduced
insulin production, as previously described (Miettinen et al. 2006). The aim of Study
IV was to characterize the development of the renal injury of the E1-DN mice. The
blood glucose levels of the homozygous mice were significantly higher than in the
heterozygous or wild type mice at all the time points (p < 0.05, n=6-16 per group),
although in line with the previous results, the levels gradually declined in the older
age (Study IV, Fig.1A). The heterozygous E1-DN mice were hyperglycaemic at
young age, but later their blood glucose levels did not differ significantly from the
wild type mice. The diabetic E1-DN homozygous mice were polyuric, and at young
age, parallel with the hyperglycaemia, also the heterozygous E1-DN mice had
increased urine volumes (Study IV, Fig.1B). The albumin excretion rate (AER) was
monitored by 24 hour urine collections in metabolic cages. Elevated AER in
homozygous E1-DN mice was detected already at the age of 10 weeks (330 ?g/24h in
homozygous vs. 130 ?g/24h in wild type, p < 0.01, n = 9-16) (Figure 8). At 20 weeks
the increase in AER continued. Some of the homozygous E1-DN mice developed
massive albuminuria, and the mean values of AER were 1257 ?g/24h in homozygous
and 269 ?g/24h in wild type (p < 0.01, n = 9-13). The level of albuminuria varied
between individual mice in the homozygous E1-DN group; the mice with the most
severe hyperglycaemia developed the most severe albuminuria (Figure 8).
Figure 8. Increased AER of the homozygous E1-DN mice was detected both at 10
and 20 weeks of age (** p < 0.01, Mann-Whitney U-test). The heterozygous mice did
not develop albuminuria. AER was correlated to blood glucose at 20 weeks, r =0.71, p
< 0.001 (Spearman’s rho), n = 22. Samples giving the ‘high’ code from the
glucometer where analysed as having the blood glucose value of 33.3 mM.
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5.4.2  E1-DN mice develop histological and structural abnormalities in the
kidney
Histological stainings indicated mesangial expansion, the key pathologic feature of
human diabetic nephropathy (Fioretto, Mauer 2007), in the homozygous E1-DN mice.
Mesangial area was visualized by Periodic acid-Schiff (PAS) staining, and diffuse
mesangial expansion was observed in the homozygous E1-DN mice aged 20 to 50
weeks (Study IV, Fig.2). When the slides were examined by a pathologist blinded
from the genotypes, the mesangial matrix accumulation was classified as focal
glomerular sclerosis in two E1-DN mice with the highest albumin excretion. In
addition, PAS positive glomerular area was measured from 70 glomeruli from seven
homozygous E1-DN mice (ages 20 to 50 weeks) and 30 glomeruli from three wild-
type mice (ages 50 weeks), and found to be increased in the glomeruli of the
homozygous E1-DN mice (Study IV, Fig.2), confirming the result of the visual
evaluation. Tubular atrophy, another histological feature of diabetic nephropathy
(Bader et al. 1980), was observed in the kidneys of the albuminuric homozygous E1-
DN mice, which exceeded albumin excretion 1000 ?g/ 24 h at 20 weeks age (Study
IV, Fig.3A-B). On structural level, irregular glomerular basement membrane
thickening was detected in the homozygous E1-DN mice by electron microscopy
(Study IV, Fig.7). The width of the basement membrane was 43% higher in the
homozygous E1-DN mice when compared to wild-type mice (p = 0.025, Mann-
Whitney U-test). Podocyte foot process widening was also observed in the
albuminuric homozygous E1-DN mice.
5.4.3  Increased glomerular apoptosis, increased tubular proliferation and
reduced nephrin expression are possible pathogenic mechanism of renal injury
in the E1-DN mice
Increased glomerular apoptosis has been suggested to contribute to the podocyte loss
in diabetes (Verzola et al. 2007a). To analyse glomerular apoptosis in the E1-DN
mice, apoptotic cells were stained for activated caspase 3, and counted from 10
glomeruli from each mouse (n=4-8 mice per group) by two researchers independently.
The number of apoptotic cells was found to be increased in the glomeruli of E1-DN
homozygous mice when compared to wild-type and heterozygous E1-DN mice at the
age of 20 weeks (6.5 vs. 1.0 apoptotic cells per 10 glomeruli, p<0.02), and in the old
mice of 56-57 weeks (9.8 vs. 4.4 apoptotic cells per 10 glomeruli, p<0.02) (Study IV,
Fig.4). Increased proliferation of tubular cells has been previously observed in
experimental diabetes (Rasch, Norgaard 1983, Mozaffari et al. 2012). To detect
proliferating cells in the E1-DN mice, kidney sections were stained with a
proliferation marker Ki-67 (Study IV, Fig.3C-D). Increased proliferation was
observed in the homozygous E1-DN mice with atrophic tubular epithelia
(proliferation index 0.70%), whereas in the wild-type mice only occasional
proliferating cells were detected (proliferation index 0.18%) (p<0.01, n=3-4 mice per
group). The glomerular expression of nephrin, a podocyte protein essential for the slit
diaphragm structure and function, was found to be reduced in the homozygous E1-DN
mice (Study IV, Fig.5). Nephrin expression was studied by immunofluorescence
staining and confocal microscopy. Quantification of the expression level of nephrin
from three albuminuric E1-DN homozygous and two wild type mice, five glomeruli
per mouse, demonstrated a lower expression level in homozygous E1-DN mice when
compared to wild-type mice (p < 0.01, Student’s t-test).
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6  DISCUSSION
6.1  Function of SHIP2 in podocytes
The lipid phosphatase SHIP2 was identified as new interaction partner of CD2AP, an
adaptor protein essential for podocyte function in maintaining the glomerular filtration
barrier (Shih et al. 1999). SHIP2 is a lipid phosphatase that hydrolyzes the 5-position
phosphate of phosphoinositol(3,4,5)trisphosphate (PI(3,4,5,)P3) to generate
phosphoinositol(3,4)bisphosphate (PI(3,4) P2), and thus negatively regulates the PI3K
pathway (Figure 5) activated by tyrosine kinase receptors of several growth factors
(Pesesse et al. 2001, Blero et al. 2001). SHIP2 has been linked to insulin resistance
and diabetes in mouse models.  SHIP2 overexpression in mice impairs glucose
tolerance (Kagawa et al. 2008, Fukui et al. 2005), and vice versa, deletion of SHIP2
protects from high fat diet- induced obesity and insulin resistance (Sleeman et al.
2005).
SHIP2 protein contains a catalytic phosphatase domain in the central part of the
protein. In addition, it has several protein-protein interaction domains: an N-terminal
SH2 domain, a C-terminal proline-rich region with SH3 domain binding sites and a
potential phosphotyrosine domain-binding site (NPXY), and a C-terminal SAM
domain (Backers et al. 2003). The transcriptional control of SHIP2 expression is not
fully characterised, but transcription factors Sp1 and Sp3 have been shown to regulate
SHIP2 expression (Ishida et al. 2005). Interestingly, the activity of Sp1 can be
controlled by hyperglycaemia-induced modifications (Du et al. 2000).
The expression and function of SHIP2 in the kidney had not been studied before.
Since podocytes were reported to be insulin responsive cells (Coward et al. 2005), the
role of SHIP2 in the regulation of insulin signalling in podocytes was investigated.
First, SHIP2 was found to be expressed in mouse and rat glomeruli, and the
intracellular interaction of CD2AP and SHIP2 was confirmed.  Previous studies with
myotubes and adipocytes had indicated that SHIP2 downregulates insulin-induced
Akt activation, and similarly, overexpression of SHIP2 in cultured podocytes lead to
reduced Akt phosphorylation and activation. These results suggest that control
mechanisms for PI3K pathway function similarly in podocytes as in traditional insulin
target cells.
It has been suggested that SHIP2 activity is controlled by tyrosine phosphorylation
(Pesesse et al. 2001, Batty et al. 2007), but results are somewhat controversial, as
other studies have shown that the critical regulation is mediated by serine/threonine
phosphorylation (Edimo et al. 2012). In addition to the regulation of the catalytic
activity, the function of SHIP2 is controlled by its cellular localisation. SHIP2 has to
be recruited to the plasma membrane to the vicinity of its substrate PI(3,4,5,)P3, which
has been shown to occur  in response to stimulation by growth factors (Dyson et al.
2001, Pesesse et al. 2001). The results of Study I showed that in cultured podocytes,
SHIP2 is partly translocated to the plasma membrane in response to insulin. However,
the interaction with CD2AP was not regulated by insulin. In contrast, CD2AP was
found to bind SHIP2 in its non-tyrosine phosphorylated form independently of insulin
stimulus, suggesting that the interaction of CD2AP and SHIP2 might have other
effects than the regulation of insulin signalling. Interestingly, both CD2AP and SHIP2
have previously been implicated in the regulation of the actin cytoskeleton (Kirsch et
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al. 1999, Dyson et al. 2001). After publication of the Study I, more evidence on the
regulatory role for SHIP2 in actin dynamics has emerged. It is evident, that not only
the downregulation of the PI3K pathway, but also the control of the concentration and
distribution of the different membrane-bound phosphoinositides affect cytoskeletal
dynamics (reviewed in Xie 2013). SHIP2 is also linked to signalling mediated by
GTPases, by binding to RhoA and consequently regulating PI(3,4,5,)P3 localization
and cell polarity (Kato et al. 2012). Very interestingly, SHIP2 was recently found to
be recruited to the nephrin multiprotein complex upon nephrin phosphorylation, and
through generation of PI(3,4)P2 rich clusters at the membrane, to contribute to actin
regulation together with filamin and lamellipodin in cultured podocytes
(Venkatareddy et al. 2011) . This process included SHIP2 tyrosine phosphorylation.
Thus, it can be speculated, that binding of CD2AP to the non-phosphorylated form of
SHIP2 might represent a regulatory mechanism. However, the role of the interaction
of CD2AP and SHIP2 in the regulation of actin dynamics remains to be investigated.
6.2  SHIP2 and podocyte insulin resistance
The association between insulin resistance and microalbuminuria in both diabetic
(Yip et al. 1993, Parvanova et al. 2006) and non-diabetic individuals (Palaniappan,
Carnethon & Fortmann 2003), suggests that insulin resistance can affect podocyte
function. Both PI3K and MAPK pathway-mediated insulin signalling has been
detected in podocytes (Welsh et al. 2010), as well as insulin-induced glucose uptake
(Coward et al. 2005). Futhermore, podocytes have been shown to develop insulin
resistance, since the podocyte cell line isolated from diabetic db/db mice was unable
to phosphorylate Akt in response to insulin (Tejada et al. 2008), but the regulation of
insulin signalling in podocytes had not been enlightened. The increased expression of
SHIP2 in glomeruli of insulin resistant animal models, observed in the Study I,
together with the in vitro results indicating that SHIP2 downregulates the PI3K
pathway in podocytes, introduces the upregulation of SHIP2 as one possible
mechanism inducing impaired insulin signalling in podocytes.
Previously, SHIP2 has been found to be expressed in elevated levels in the adipose
tissue and skeletal muscle of db/db mice, and recently, it was also shown to be
upregulated in the hypothalamus of db/db mice and involved in the regulation of food
intake (Ichihara et al. 2013). In Study I, SHIP2 elevation was observed in glomeruli of
both db/db mice and the obese Zucker rats, two animal models of insulin resistance
caused by a mutation in the leptin receptor gene, and characterised by hyperphagia
and obesity (Chua et al. 1996). Despite the similarities of the models, albuminuria is
initiated early in the db/db mice, at the age of eight weeks, whereas Zucker rats have
been reported to develop albuminuria at the age of 40 weeks (Sharma, McCue &
Dunn 2003a, Coimbra et al. 2000). For this reason, rat kidneys were studied at two
different time points. Interestingly, upregulation of SHIP2 was detected already
before the reported age of onset of proteinuria and before any histological changes in
the glomeruli were observed. Thus, upregulation of SHIP2 is not a secondary effect of
podocyte damage. Elevation of SHIP2 expression levels is seen in several tissues of
db/db mice, but interestingly, in this study SHIP2 was not upregulated in tubuli of
obese Zucker rats, and in the previous study, not in the liver of db/db mice (Hori et al.
2002). This suggests a tissue-specific regulation of SHIP2, potentially similar for
podocytes, myocytes and adipocytes.
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Insulin sensitising-agents thiazolidinediones have renoprotective functions, which can
also be considered as an indicator of the link between insulin resistant state and
diabetic nephropathy. Treatment with rosiglitazone diminished the development of
albuminuria in streptozotocin-induced diabetic mice, a model of type 1 diabetes,
without altering hyperglycaemia (Zhang et al. 2008). Further, in the same study,
rosiglitazone prevented podocyte loss and reduced oxidative markers in diabetic
mouse glomeruli. Rosiglitazone has also been shown to prevent palmitate-induced
insulin resistance in cultured podocytes (Lennon et al. 2009b). Interestingly, the
elevated levels of SHIP2 in the muscle and fat of db/db mouse were decreased with
rosiglitazone treatment (Hori et al. 2002).
The possible effects of podocyte insulin resistance for their function can be
speculated. It seems controversial that reduced glucose uptake would be harmful,
since the excess of intracellular glucose is the major cause of diabetic complications,
although podocyte-specific overexpression of GLUT1 was found to reduce mesangial
expansion, contrary to expectations (Zhang et al. 2010). Since the molecules of the
insulin signalling pathway are connected to actin regulation, and functional dynamic
cytoskeleton is crucial for podocyte function, podocyte insulin resistance could
contribute to the development of proteinuria by altering actin regulation. In addition,
Akt phosphorylation has been identified as a key survival signal in podocytes (Huber
et al. 2003), and reduced signalling through the PI3K pathway in insulin resistance
could predispose to apoptosis. Since selective impairment of PI3K mediated insulin
signalling can lead to overstimulation of the MAPK pathway in hyperinsulinemic
state (Cusi et al. 2000), this could promote secretion of cytokines and ET-1 (Formoso
et al. 2006). However, up to date, there is no direct evidence of podocyte insulin
resistance in vivo. Alternatively, the association of systemic insulin resistance and
microalbuminuria could be mediated through inflammatory pathways and endothelial
dysfunction promoting podocyte injury and proteinuria (Overviewed in Figure 4). In
this case, as well, podocyte dysfunction is an early event in an insulin resistant state.
6.3  Apoptosis in cultured podocytes and diabetic animal models in
relation to glomerular pathology
In Study I, SHIP2 overexpression was found to substantially increase the apoptosis
rate in differentiated podocytes, in which apoptosis is normally detected in low levels.
Also in vivo, in diabetic E1-DN mice (Study IV), apoptotic glomerular cells were
sparse, but significantly increased in diabetic homozygous E1-DN mice. Interestingly,
the number of apoptotic cells in glomeruli was higher in diabetic mice at both one
year of age and at 20 weeks of age, when the histological changes in glomeruli were
still mild. Since podocytes are terminally differentiated cells, even a small increase in
the rate of apoptosis could contribute to the development of the glomerular injury.
Previously, in the db/db mouse model, increased podocyte apoptosis has been
reported to precede the increase in urinary albumin excretion (Susztak et al. 2006). In
addition, analyses of kidney biopsies of human patients with diabetes have shown six
fold higher apoptosis rate already in early nephropathy, and the rate remained similar
in advanced nephropathy (Verzola et al. 2007a).
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Reduced number of podocytes has been reported in both type 2 (Pagtalunan et al.
1997b) and type 1 diabetes, where it was detected already after short duration (Steffes
et al. 2001). In addition to apoptosis, podocyte loss can result from podocyte
detachment. In fact, detachment of podocyte foot processes, and even denuded areas
of the glomerular basement membrane, have been quite recently described both in
patients with type 1 and type 2 diabetes (Toyoda et al. 2007, Weil et al. 2012)(Toyoda
et al. 2007, Toyoda et al. 2007). Previously basement membrane denudation has been
detected in focal segmental glomerulosclerosis (Grishman, Churg 1975), and it has
been suggested to constitute an important part of the pathogenesis of glomerular
sclerosis, as the bare basement membrane has been described to form attachments
with the Bowman’s capsule (Kriz, Gretz & Lemley 1998). In electron microscopic
analyses of the diabetic E1-DN mice (Study IV), no denuded areas of GBM were
observed. However, basement membrane denudation is not a predominant
phenomenon of diabetic nephropathy, and has not been reported in the original
electron microscopic studies on renal biopsies of diabetic patients (Osterby 1972, Ellis
et al. 1987) or on kidneys of diabetic rats (Steffes et al. 1980). Instead, basement
membrane thickening has been reported in many structural studies on diabetic
nephropathy (Fioretto et al. 1995, Osterby 1972), and it has been now included as a
criterion in the pathologic classification of diabetic nephropathy (Tervaert et al.
2010). Basement membrane thickening was observed in diabetic E1-DN mice (Study
IV), both as irregular bulging, and when measured from the regularly shaped areas
and compared to wild-type mice. Widening of podocyte foot processes, surrounding
the glomerular capillaries, was also evident in the most albuminuric E1-DN mice.
Foot process widening constitutes a known structural feature of diabetic nephropathy
(Ellis et al. 1987, Berg et al. 1998).
Mesangial expansion is the key histological finding in diabetic nephropathy (Fioretto,
Mauer 2007), also associated with the risk of disease progression (Fioretto et al.
1995). Expansion of the mesangial area is mainly due to mesangial matrix
accumulation, which can eventually lead to the formation of nodular sclerosis
(Kimmelstiel, Wilson 1936). Histological analyses revealed mesangial expansion in
diabetic E1-DN mice (Study IV), and in the most albuminuric mice the finding was
classified as focal sclerosis, resembling human diabetic nephropathy. Interestingly,
similar sclerosis has been described in CD2AP +/- mice (Kim et al. 2003), and in
Study III, polymorphisms in the CD2AP gene were associated with ESRD and
estimated glomerular filtration rate, closely linked to the glomerular sclerosis.
6.4 The effects of hyperglycaemia in cultured podocytes and diabetic
animal models
Studies on E1-DN mice (Study IV), showed that prolonged hyperglycaemia was the
most important factor determining the development of albuminuria and glomerular
pathology, as expected. There was substantial variation in the renal phenotype of the
homozygous E1-DN mice, but this could be clearly explained by the variation in
blood glucose. At the age of 20 weeks, a strong correlation between blood glucose
and AER was detected. Correspondingly, it is evident from clinical studies, that poor
glycaemic control is the main risk factor for microvascular complications
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(EURODIAB 1994, UK Prospective Diabetes Study (UKPDS) Group 1998), and
readily understandable from the pathogenetic view.
Hyperglycaemia is also known to induce cellular insulin resistance by the
glycotoxicity mechanisms (Tomas et al. 2002). In the Study I, lipid phosphatase
SHIP2, a negative regulator of insulin signalling, was found to be elevated in the
glomeruli of diabetic db/db mice and obese Zucker rats. However, in cultured
podocytes, high glucose concentration did not affect SHIP2 expression levels,
suggesting that hyperglycaemia is not the main factor inducing SHIP2 upregulation in
diabetic mice. On the other hand, the possibility that high glucose concentrations
could affect SHIP2 expression in glomeruli in vivo, after longer exposition, cannot be
excluded. However, also the results from animal models (Study I) suggest that
upregulation of SHIP2 does not depend on hyperglycaemia, as SHIP2 was
upregulated also in the obese Zucker rats, which did not have significantly elevated
blood glucose levels.
6.5  INPPL1 gene, the metabolic syndrome and diabetic nephropathy
SHIP2 protein is encoded by the INPPL1 gene. Previously, several studies have
reported associations between polymorphisms in the INPPL1 gene and the metabolic
syndrome or type 2 diabetes. First, a 16-base pair deletion in the 3’ untranslated
region (UTR) was found more frequently in patients with type 2 diabetes than in
controls (Marion et al. 2002), and additionally, this mutation was shown to upregulate
the expression of SHIP2 protein in vitro. Next, three single nucleotide polymorphisms
in the INPPL1 gene were found to be significantly associated with the components of
the metabolic syndrome in a British cohort, but these associations could not be
replicated in French subjects (Kaisaki et al. 2004). In addition, two studies from the
Japanese population have shown associations between the INPPL1 gene and type 2
diabetes or impaired fasting glucose (Kagawa et al. 2005, Ishida et al. 2006). The
importance of the components of the metabolic syndrome, with insulin resistance as
underlying mechanism, in the pathogenesis of diabetic nephropathy is evident.
However, it has not been previously investigated, if the same genetic factors
contribute to the metabolic syndrome in patients with type 1 diabetes as in patients
with type 2 diabetes and in the general population.
Study II found associations between two polymorphisms in the INPPL1 gene and the
metabolic syndrome in Finnish patients with type 1 diabetes. One of these SNPs,
rs2276047, was previously reported to be associated with the metabolic syndrome in
British patients of type 2 diabetes and their family members (Kaisaki et al. 2004).
Interestingly, the association was detected also in this study, despite totally different
study population. In addition, the British study reported associations of two other
markers, rs9886 and a 28bp insertion/deletion polymorphism in intron 1, with the
metabolic syndrome. Analysis of rs9886 in Study II did not reveal significant
associations, and the insertion/deletion polymorphism was not genotyped. In the
Japanese studies (Kagawa et al. 2005, Ishida et al. 2006), new SNPs were identified,
but as those SNPs are not found in the publicly available databases, and their allele
frequencies in the European population are not known, they were not included in
Study II. Interestingly, minor allele frequencies for the SNPs in the INPPL1 gene
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differ considerably between populations from different continents (HapMap
database), but the allele frequencies reported here for Finnish patients with type 1
diabetes resemble the minor allele frequencies for the general population with
European origin.
In Study II, the significant associations with the metabolic syndrome were found with
rs2276048, a silent mutation in exon 9, and rs2276047 in intron 9. The haplotype
analysis indicated that these two SNPs are inherited in the same haplotype block, and
thus might represent a common causative mutation linked to both markers.
Furthermore, the lower risk for the metabolic syndrome was associated with the
genotypes homozygous for the minor allele of the markers, suggesting a recessive
protective effect that could be due to a loss of function variant. This suggestion is
consistent with the knowledge of the function of SHIP2, the protein coded by
INPPL1, in the downregulation of insulin signalling. Also in animal models, loss or
reduction of the function of SHIP2 has been found to be protective against insulin
resistance and obesity (Sleeman et al. 2005, Buettner et al. 2007, Grempler et al.
2007).
Body composition and obesity have been found to have sex-specific genetic factors in
genome-wide association and linkage scans (Lindgren et al. 2009, Sammalisto et al.
2009). In addition, systolic blood pressure, HDL and triglycerides were shown to
belong to traits with sex-specific linkage results (Weiss et al. 2006). Since all of these
features are the components of the metabolic syndrome, the association analyses in
Study II were stratified by gender. Interestingly, the significant associations with the
metabolic syndrome were strictly restricted to men, whereas in women the genotypes
of the markers were equally distributed. This a new finding, not observed in the
previous studies reporting associations between the INPPL1 gene and the metabolic
syndrome or type 2 diabetes (Marion et al. 2002, Kaisaki et al. 2004, Kagawa et al.
2005, Ishida et al. 2006). Neither are there any reports on differences in the
expression or function of the SHIP2 protein between the sexes. Thus, the reason for
the sex-specific association of INPPL1 and the metabolic syndrome remains to be
clarified. Apart from a truly different mechanism, the differences in associations
could be due to the separate cut-off values for HDL and waist circumference for men
and women in the criteria of the metabolic syndrome, that could result in slightly
differently defined phenotypes. However, this seems not to be the case, because when
the different components of the metabolic syndrome were analysed as quantitative
traits, not even trends were observed in female patients. In contrast, in male patients
there was a linear trend, although statistically not significant, towards lower blood
pressure and waist circumference in carriers of the minor alleles of the same SNPs,
which were associated with the metabolic syndrome. Also for male patients, the
association with the metabolic syndrome was found to be substantially stronger as an
entity than with any of its components separately.
The metabolic syndrome is not a true syndrome, but rather a cluster of features related
to insulin resistance. In patients with type 1 diabetes, the initial mechanisms of insulin
resistance may differ from the general population, since insulin resistance is mainly
induced by hyperglycaemia, not by obesity. However, a previous FinnDiane study
discovered that insulin resistant state, defined by reduced estimated glucose disposal
rate, was associated with the metabolic syndrome also in patients with type 1 diabetes
(Thorn et al. 2005). Further, the metabolic syndrome was found to be more frequent
in patients with type 1 diabetes than in the general population (Thorn et al. 2005). In
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Study II, the same genetic polymorphism (rs2276047) previously associated with the
metabolic syndrome (Kaisaki et al. 2004), was found with significant association also
in patients with type 1 diabetes.
In Study II, the markers in the INPPL1 gene were tested also for association with
diabetic nephropathy, but no associations were found. However, a strong association
between the phenotypes of the metabolic syndrome and diabetic nephropathy was
observed, in line with the earlier results from the FinnDiane cohort (Thorn et al.
2005). It is not surprising that the same genes are not linked to diabetic nephropathy
and the metabolic syndrome, as diabetic nephropathy is a multifactorial disease with
several genetic and environmental predisposing factors. In addition, the association
between the metabolic syndrome and diabetic nephropathy is probably causative to
both directions. Insulin resistance has been implicated mainly in the early steps of the
pathogenesis of diabetic nephropathy, predicting the development of albuminuria
(Orchard et al. 2002, Ekstrand, Groop & Gronhagen-Riska 1998). On the other hand,
when the disease progresses, reduced renal function induces elevated blood pressure
and lipid abnormalities, which are components of the metabolic syndrome. This
hypothesis of the two-way causality is supported by the results of a previous
prospective study from FinnDiane, identifying the metabolic syndrome as a predictor
of cardiovascular events, but not of progression of diabetic nephropathy in patients
with type 1 diabetes (Thorn et al. 2009).
6.6  CD2AP gene, diabetic nephropathy and end stage renal disease
The importance of the adaptor protein CD2AP in the filtration function of podocytes
has been demonstrated by studies on CD2AP knockout mice. The mice homozygous
for CD2AP deletion develop early proteinuria and lethal nephrosis (Shih et al. 1999),
whereas the CD2AP heterozygous mice present glomerular sclerosis at an older age
(Kim et al. 2003). In addition, mutations in the CD2AP gene have been found in
human patients with focal segmental glomerulosclerosis (FSGS) (Kim et al. 2003,
Gigante et al. 2009), a form of nephrotic syndrome with frequent progression to end
stage renal disease (ESRD) and histological findings with similarities to the
histopathology of diabetic nephropathy. Study III aimed to test the hypothesis that
mutations or variants in the CD2AP gene could predispose patients with diabetes to
glomerular injury and nephropathy.
Two polymorphisms in the CD2AP gene, rs9369717 and rs9349417, were found to
associate with ESRD in Finnish patients with type 1 diabetes. The associations were
confirmed by meta-analysis of Finnish, Danish and Italian cohorts. In addition, a third
SNP, rs6936632, was associated with ESRD in the meta-analysis of Finnish, Danish,
Italian and UK-ROI patients. Results from the genotypic association analysis in the
Finnish, Danish and Italian cohorts demonstrated an effect in same direction.
All these three SNPs were intronic, and rs9369717 and rs9349417 were in strong LD
with each other. The intronic polymorphisms are not likely to be causative to disease,
although also intronic polymorphisms can affect the expression of genes. Rather, it
can be speculated that a causative variant would be inherited together with these
markers. Interestingly, a polymorphism in the CD2AP gene has been recently found
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in a genome wide scan to be associated with Alzheimer’s disease (Naj et al. 2011).
The SNPs associated with ESRD in Study III, rs9369717 and rs9349417, are in LD
with the Alzheimer’s disease SNP (rs9349407), which is intronic as well (HapMap
database). In Study III, the minor alleles of the SNPs were identified as risk alleles for
ESRD in the additive genotypic model, presenting another similarity to the SNP in
Alzheimer’s disease.
Time-to-ESRD analyses were also performed in Study III. When all the patients were
included in the analysis, rs9249417 was found to associate with faster progression to
ESRD, supporting the association found in the cross-sectional association analysis.
When only those patients who eventually developed ESRD were included, rs9369717
was associated with the rate of ESRD development, this being an independent result
from the original association with ESRD. In addition, in the cross-sectional analysis,
ESRD patients excluded, rs9369717 was associated with estimated glomerular
filtration rate (eGFR), possibly reflecting the ongoing process of developing renal
failure. Genetic association with ESRD in patients with diabetes might be due to
survival bias, since diabetic nephropathy, already at the macroalbuminuria stage, is
associated with significantly increased mortality (Groop et al. 2009, Adler et al.
2003). Thus, a genetic variant with protective effects could be enriched in the patients
with ESRD. Therefore, a competing risk analysis comparing the risks of ESRD and
pre-ESRD death in relation to the CD2AP gene polymorphisms was performed in
Study III.  No associations between the SNPs and death were observed, suggesting
that the minor alleles of the SNPs are truly increasing the risk of ESRD and not
protecting from death.
In Study III, the CD2AP gene variants were not associated with diabetic nephropathy,
defined as macroalbuminuria or ESRD, in four European populations when analysed
separately or in the meta-analysis. However, the associations were found specifically
with ESRD in patients with type 1 diabetes. The associations restricted to ESRD in
patients with diabetes may appear surprising, when the classical course of diabetic
nephropathy, trough proteinuric stages, is considered. Interestingly, the results from
the GENIE consortium, combining three genome-wide association studies in a meta-
analysis, also identified genetic markers associated solely to ESRD, and not to
diabetic nephropathy (Sandholm et al. 2012). At the same time, the search for diabetic
nephropathy genes has not discovered strong associations (Williams et al. 2012,
Sandholm et al. 2012). Together, these results propose that different genetic risk
factors can influence the susceptibility of progression in the different stages of the
disease.
Furthermore, it is not known if there is a causal relationship between proteinuria and
the decline in renal function, despite the temporal relationship. The same risk factors
and pathogenic pathways can affect both processes in parallel (Figure 4). In addition,
recent studies have indicated that the reduction of the filtration function can develop
without preceding albuminuria (Molitch et al. 2010), and reported reduced GFR
combined with histological glomerular changes, typical for diabetic nephropathy, in
patients with type 1 diabetes and normal AER (Caramori, Fioretto & Mauer 2003).
Podocyte injury and dysregulation are essential factors in both glomerular sclerosis
and proteinuria, and interestingly, CD2AP protein is involved in both processes.
Previous studies on CD2AP deficient mice (Shih et al. 1999, Kim et al. 2003) and the
fact that CD2AP is associated with FSGS in human patients (Kim et al. 2003, Gigante
et al. 2009), suggest that defects in the function of CD2AP in podocytes could
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predispose both to albuminuria and impaired filtration. This supports the relevance of
the association between CD2AP gene and ESRD in patients with diabetes, found in
Study III.
6.7  Comparison of the E1-DN mouse with other mouse models of
nephropathy
Many of the mouse models of diabetes develop only modest glomerular lesions.
When compared to other models, the E1-DN mice in FVB background develop
substantial albuminuria and advanced glomerular pathology. The renal phenotype is
purely secondary to the persistant hyperglycaemia, as the transgene, kinase-negative
EGF-R, is expressed only in pancreatic islet ?-cells, resulting in early-onset
insulinopenic diabetes. Thus the E1-DN mouse model mimics human type 1 diabetes
with poor glycaemic control.
In addition to the transgene not being expressed in the kidney, no exogenous
compounds are used for diabetes induction in the E1-DN mice. One of the most
widely used murine models of diabetes is streptozotocin-induced destruction of
pancreatic ?-cells. Streptozotocin-treated rodents develop diabetes and
hyperglycaemia-induced renal injury, but also the possible toxic effects of
streptozotocin on the kidney need to be taken into consideration. Another widely used
model is the db/db mouse, which is diabetic due to a mutation in the leptin receptor
gene. The obese and insulin resistant phenotype of the db/db mouse is quite different
from the insulinopenic E1-DN mouse. Thus, these models can offer possibilities to
study different aspects of the pathogenesis of diabetic nephropathy. In any case, the
db/db mouse serves as a good model for type 2 diabetes and albuminuria, although
does not develop severe glomerular changes (Sharma, McCue & Dunn 2003b).
The E1-DN mice show similarities with the OVE26 and Akita mice, two other models
with defects in insulin production. The OVE26 mice in FVB background are diabetic
due to overexpression of calmodulin in pancreatic ?-cells. They present severe
glomerulopathy, in addition to especially high albuminuria (Zheng et al. 2004), thus
being a promising mouse model of diabetic renal disease. The Akita mice have a
spontaneous mutation in insulin 2 gene, and develop a modest renal phenotype in the
original C57BL/6 strain (Gurley et al. 2010). When crossed to FVB/NJ background,
the Akita mice progress to high proteinuria with moderate mesangial expansion
(Chang et al. 2012). It has become evident that the background strain of the mouse
model is extremely important for the development of renal injury. Interestingly, the
FVB background has appeared to be susceptible for renal disease, and thus may
contribute to the relatively severe phenotype of the E1-DN mice.
One disadvantage of the E1-DN model is the large variation in the severity of the
renal phenotype between the individual mice, although related to the blood glucose
levels. This means that a large number of mice are needed if the model is used for e.g.
intervention studies. The histological and structural changes in glomeruli were
detected relatively late in the E1-DN mice, as in most of the other mouse models.
Since overt human diabetic nephropathy usually develops after 15 to 20 years of
diabetes duration, it may not be possible to produce a mouse model, which would
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develop renal changes very early, if the pathogenetic mechanisms are expected to be
similar to the human disease.
Reduced expression of nephrin, the key molecule of the podocyte slit diagphagm
structure, has been suggested to contribute to the development of diabetic
nephropathy. Interestingly, nephrin expression was found to be decreased in the
glomeruli of the albuminuric E1-DN mice. This is in line with the results from
previous studies, which have reported reduced level of nephrin protein in the
streptozotocin mouse model (Menne et al. 2006) and in renal biopsies of human
patients with diabetic nephropathy (Doublier et al. 2003b). Whether this is causative
or secondary to podocyte injury, remains to be confirmed. However, based to both
earlier studies and Study IV, showing unaltered expression of two other podocyte
molecules, CD2AP and podocin (Menne et al. 2006, Benigni et al. 2004), it can be
suggested that the down-regulation of nephrin is a selective change.
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7 SUMMARY AND CONCLUSIONS
The present studies concentrated on two molecules expressed by podocytes, CD2AP
and SHIP2, and applied different approaches to investigate them in podocytes and in
the pathogenic processes of diabetic nephropathy. Biochemical methods were used to
characterise the interaction of the proteins, cell culture experiments and diabetic
animal models to study the expression and function of the molecules, and a candidate
gene approach was undertaken to assess their role in the genetic susceptibility to
diabetic nephropathy.
Study I showed that glomerular podocytes express lipid phosphatase SHIP2. When
overexpressed in cultured podocytes, SHIP2 downregulates insulin signalling and
promotes apoptosis. CD2AP binds to the non-tyrosine-phosphorylated form of SHIP2,
independently of insulin stimulation. Since both of the proteins are involved in the
regulation of the actin cytoskeleton in podocytes, this interaction might have a role in
maintaining the functional cytoskeleton, crucial for the function of podocytes.
However, further studies are needed to confirm this hypothesis. The expression of
SHIP2 was found to be elevated in the glomeruli of diabetic rats prior to the
development of proteinuria, suggesting that the upregulation of SHIP2 is not a
secondary effect to glomerular damage, but rather might be involved in the
development of podocyte injury.  In conclusion, these results demonstrate a possible
mechanism for insulin resistance in podocytes.
In Study II, two polymorphisms in the INPPL1 gene, encoding for SHIP2 protein,
were found to be associated with the metabolic syndrome in male patients with type 1
diabetes. One of these SNPs has earlier been reported to be associated with the
components of the metabolic syndrome in patients with type 2 diabetes and their
relatives, and the association was replicated in this study, despite the different study
population. No associations between the SNPs covering the INPPL1 gene and diabetic
nephropathy were revealed. These results suggest that INPPL1 gene variants may
contribute to the susceptibility to the metabolic syndrome in men with type 1 diabetes,
but not to diabetic nephropathy.
In Study III, two polymorphisms in the CD2AP gene were found to be associated with
ESRD in Finnish patients with type 1 diabetes, and the associations were replicated by
meta-analysis of the original and two additional cohorts. In addition, a third
polymorphism was associated with ESRD by meta-analysis of four European cohorts.
However, the CD2AP gene was not associated with diabetic nephropathy. The results
of this study suggest that the CD2AP gene variants may contribute to the risk of
ESRD in patients with diabetes.
The polymorphisms in the INPPL1 and CD2AP genes that were associated with the
metabolic syndrome or with ESRD, do not change the amino acid composition of
CD2AP or SHIP2 proteins, suggesting that these polymorphisms are rather markers
than causative variants. Sequencing of the genes from the same patient cohorts could
clarify, if this is the case. In addition, the effect of the intronic polymorphisms on the
expression or splicing of the proteins could be studied by in vitro assays.
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Study IV describes the renal phenotype of the transgenic E1-DN mice. The E1-DN
mice express a kinase-negative EGF-R in their pancreatic islets and have early-onset
diabetes due to reduced insulin production. The renal injury is secondary to persistent
hyperglycaemia. The homozygous E1-DN mice were found to develop substantial
albuminuria, mesangial expansion, and in most severe cases, glomerular sclerosis. On
structural level, thickening of the glomerular basement membrane and podocyte foot
process widening were observed. Reduced expression of nephrin, increased
glomerular apoptosis and tubular proliferation were identified as mechanisms that
might contribute to the development of the renal injury. In future, also the renal
function of these mice needs to be assessed. In conclusion, the observed changes
resemble human diabetic nephropathy, and the E1-DN mice can serve as a good
model to study the mechanisms of diabetic nephropathy.
Taken together, diabetic nephropathy is a multifactorial disease with several
environmental and genetic components, that influence the different pathogenic
mechanisms and the different stages of the disease. In this study series, the candidate
gene studies were negative for association of the INPPL1 and CD2AP genes with
diabetic nephropathy, but by both experimental and genetic approaches, the SHIP2
and CD2AP molecules were associated with several features of diabetic nephropathy:
insulin resistance, the metabolic syndrome, podocyte apoptosis and end stage renal
disease. In addition, the development of renal injury, with several pathological
findings resembling human diabetic nephropathy, was described in a diabetic mouse
model.
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The Finnish Diabetic Nephropathy Study Centers
Anjalankoski Health Centre S. Koivula, T. Uggeldahl
Central Finland Central Hospital, Jyväskylä T. Forslund, A. Halonen, A. Koistinen, P. Koskiaho,
M. Laukkanen, J. Saltevo, M. Tiihonen
Central Hospital of Åland Islands, Mariehamn M. Forsen, H. Granlund, A-C. Jonsson, B. Nyroos
Central Hospital of Kanta-Häme, Hämeenlinna P. Kinnunen, A. Orvola, T. Salonen, A. Vähänen
Central Hospital of Länsi-Pohja, Kemi H. Laukkanen, P. Nyländen, A. Sademies
Central Ostrobothnian Hospital District,
Kokkola
S. Anderson, B. Asplund, U. Byskata, P. Liedes,
M. Kuusela, T. Virkkala
City of Espoo Health Centre
Espoonlahti A. Nikkola, E. Ritola
Tapiola M. Niska, H. Saarinen
Samaria E. Oukko-Ruponen, T. Virtanen
Viherlaakso A. Lyytinen
City of Helsinki Health Centre
Puistola H. Kari, T. Simonen
Suutarila A. Kaprio, J. Kärkkäinen, B. Rantaeskola
Töölö P. Kääriäinen, J. Haaga, A-L. Pietiläinen
City of Hyvinkää Health Centre S. Klemetti, T. Nyandoto, E. Rontu, S. Satuli-Autere
City of Vantaa Health Centre
Korso R. Toivonen, H. Virtanen
Länsimäki R. Ahonen, M. Ivaska-Suomela, A. Jauhiainen
Martinlaakso M. Laine, T. Pellonpää, R. Puranen
Myyrmäki A. Airas, J. Laakso, K. Rautavaara
Rekola M. Erola, E. Jatkola
Tikkurila R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo
Heinola Health Centre P. Hentunen, J. Lagerstam
Helsinki University Central Hospital,
Department of Medicine, Division of
Nephrology
A. Ahola, M. Feodoroff, D. Gordin, O. Heikkilä,
K Hietala, J. Kytö, S. Lindh, K. Pettersson-Fernholm,
A. Sandelin, A-R Salonen, L. Salovaara, L. Thorn,
J. Tuomikangas, T. Vesisenaho, J. Wadén
Herttoniemi Hospital, Helsinki V. Sipilä
Hospital of Lounais-Häme, Forssa T. Kalliomäki, J. Koskelainen, R. Nikkanen, N. SavolainenH. Sulonen, E. Valtonen
Iisalmi Hospital E. Toivanen
Jokilaakso Hospital, Jämsä A. Parta, I. Pirttiniemi
Jorvi Hospital, HUCH, Espoo S. Aranko, S. Ervasti, R. Kauppinen-Mäkelin, A. Kuusisto,
T. Leppälä, K. Nikkilä, L. Pekkonen
Jyväskylä Health Centre K. Nuorva, M. Tiihonen
Kainuu Central Hospital, Kajaani S. Jokelainen, P. Kemppainen, A-M. Mankinen, M. Sankari
Kerava Health Centre H. Stuckey, P. Suominen
Kirkkonummi Health Centre A. Lappalainen, M. Liimatainen, J. Santaholma
Kivelä Hospital, Helsinki A. Aimolahti, E. Huovinen
Koskela Hospital, Helsinki V. Ilkka, M. Lehtimäki
Kotka Heath Centre E. Pälikkö-Kontinen, A. Vanhanen
Kouvola Health Centre E. Koskinen, T. Siitonen
Kuopio University Hospital E. Huttunen, R. Ikäheimo, P. Karhapää, P. Kekäläinen,
M. Laakso, T. Lakka, E. Lampainen, L. Moilanen,
L. Niskanen, U. Tuovinen, I. Vauhkonen, E. Voutilainen
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Kuusamo Health Centre T. Kääriäinen, E. Isopoussu
Kuusankoski Hospital E. Kilkki, I. Koskinen, L. Riihelä
Laakso Hospital, Helsinki T. Meriläinen, P. Poukka, R. Savolainen, N. Uhlenius
Lahti City Hospital A. Mäkelä, M. Tanner
Lapland Central Hospital, Rovaniemi L. Hyvärinen, S. Severinkangas, T. Tulokas
Lappeenranta Health Centre P. Linkola, I. Pulli
Lohja Hospital T. Granlund, M. Saari, T. Salonen
Loimaa Health Centre A. Mäkelä, P. Eloranta
Länsi-Uusimaa Hospital, Tammisaari I-M. Jousmaa, J. Rinne
Malmi Hospital, Helsinki H. Lanki, S. Moilanen, M. Tilly-Kiesi
Mikkeli Central Hospital A. Gynther, R. Manninen, P. Nironen, M. Salminen,
T. Vänttinen
Mänttä Regional Hospital I. Pirttiniemi, A-M. Hänninen
North Karelian Hospital, Joensuu U-M. Henttula, P. Kekäläinen, M. Pietarinen, A. Rissanen,
M. Voutilainen
Nurmijärvi Health Centre A. Burgos, K. Urtamo
Oulankangas Hospital, Oulainen E. Jokelainen, P-L. Jylkkä, E. Kaarlela, J. Vuolaspuro
Oulu Health Centre L. Hiltunen, R. Häkkinen, S. Keinänen-Kiukaanniemi
Oulu University Hospital R. Ikäheimo
Päijät-Häme Central Hospital H. Haapamäki, A. Helanterä, S. Hämäläinen, V. Ilvesmäki,
H. Miettinen
Palokka Health Centre P. Sopanen, L. Welling
Pieksämäki Hospital V. Javtsenko, M. Tamminen
Pietarsaari Hospital M-L. Holmbäck, B. Isomaa, L. Sarelin
Pori City Hospital P. Ahonen, P. Merensalo, K. Sävelä
Porvoo Hospital M. Kallio, B. Rask, S. Rämö
Raahe Hospital A. Holma, M. Honkala, A. Tuomivaara, R. Vainionpää
Rauma Hospital K. Laine, K. Saarinen, T. Salminen
Riihimäki Hospital P. Aalto, E. Immonen, L. Juurinen
Salo Hospital A. Alanko, J. Lapinleimu, P. Rautio, M. Virtanen
Satakunta Central Hospital, Pori M. Asola, M. Juhola, P. Kunelius, M-L. Lahdenmäki,
P. Pääkkönen, M. Rautavirta
Savonlinna Central Hospital E. Korpi-Hyövälti, T. Latvala, E. Leijala
South Karelia Central Hospital, Lappeenranta T. Ensala, E. Hussi, R. Härkönen, U. Nyholm, J. Toivanen
Tampere Health Centre A. Vaden, P. Alarotu, E. Kujansuu, H. Kirkkopelto-Jokinen,
M. Helin, S. Gummerus, L. Calonius, T. Niskanen,
T. Kaitala, T. Vatanen
Tampere University Hospital I. Ala-Houhala, T. Kuningas, P. Lampinen, M. Määttä,
H. Oksala, T. Oksanen, K. Salonen, H. Tauriainen,
S. Tulokas
Tiirismaa Health Centre, Hollola T. Kivelä, L, Petlin, L. Savolainen
Turku Health Centre I. Hämäläinen, H. Virtamo, M. Vähätalo
Turku University Central Hospital K. Breitholz, R. Eskola, K. Metsärinne, U. Pietilä,
P. Saarinen, R. Tuominen, S. Äyräpää
Vaajakoski Health Centre K. Mäkinen, P. Sopanen
Valkeakoski Regional Hospital S. Ojanen, E. Valtonen, H. Ylönen, M. Rautiainen,T. Immonen
Vammala Regional Hospital I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä
Vaasa Central Hospital S. Bergkulla, U. Hautamäki, V-A. Myllyniemi, I. Rusk
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